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ABSTRACT 
 Background: Survival of patients with Acute Aortic Syndrome (AAS) may relate to the 
speed of diagnosis. Diagnostic delay is exacerbated by non classical presentations such as 
myocardial ischemia or acute heart failure (AHF). However little is known about clinical 
implications and pathophysiological mechanisms of Troponin T elevation and AHF in AAS. 
Methods and Results: Data were collected from a prospective metropolitan AAS registry 
(398 patients diagnosed between 2000 and 2013).  
Troponin T values (either standard or high sensitivity assay, HS) were available in 248 
patients (60%) of the registry population; the overall frequency of troponin positivity was 
28% (ranging from 16% to 54%, using standard or HS assay respectively, p = 0.001). 
Troponin positivity was associated with a twofold increased risk of long in-hospital 
diagnostic time (OR 1.92, 95% CI 1.05-3.52, p = 0.03), but not with in-hospital mortality. 
The combination of positive troponin and ACS-like ECG abnormalities resulted in a 
significantly increased risk of inappropriate therapy due to a misdiagnosis of ACS (OR 2.48, 
95% CI 1.12-5.54, p = 0.02).   
Patients with AHF were identified by the presence of  dyspnea as presentation symptom or 
radiological signs of pulmonary congestion or cardiogenic shock. The overall frequency of 
AHF was  28 % (32% type A vs. 20% type B AAS, p = 0.01). AHF was due to a variety of 
pathophysiological mechanisms including cardiac tamponade (26%), aortic regurgitation 
(25%), myocardial ischemia (17%), hypertensive crisis (10%). AHF was associated with 
increased surgical delay and with increased risk of in-hospital death (adjusted OR 1.97 95% 
CI1.13-3.37,p=0.01). 
Conclusions: Troponin positivity (particularly HS) was a frequent finding in AAS. Abnormal 
troponin values were strongly associated with ACS-like ECG findings, in-hospital diagnostic 
delay, and inappropriate therapy. AHF was associated with  increased surgical delay and was 
an independent predictor of in-hospital mortality. 
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INTRODUCTION 
 
Definition 
Acute aortic syndromes (AAS) are defined as emergency conditions with similar clinical 
characteristics involving the aorta (1). There is a common pathway for the various 
manifestations of AAS that eventually leads to a breakdown of the intima and media. This 
may result in intramural haematoma (IMH), penetrating aortic ulcer (PAU), or in separation 
of aortic wall layers, leading to aortic dissection (AD). AD is defined as disruption of the 
medial layer provoked by intramural bleeding, resulting in separation of the aorticwall layers 
and subsequent formation of a TL and an FL with or without communication. In most cases, 
an intimal tear is the initiating condition, resulting in tracking of the blood in a dissection 
plane within the media. This process is followed either by an aortic rupture in the case of 
adventitial disruption or by a re-entering into the aortic lumen through a second intimal tear.  
 
Pathology and classification  
Acute aortic syndromes occur when either a tear or an ulcer allows blood to penetrate from 
the aortic lumen into the media or when a rupture of vasa vasorum causes a bleed within the 
media. The inflammatory response to blood in the media may lead to aortic dilation and 
rupture. Figure 1 displays the Stanford and the DeBakey classifications.  
The Stanford type A and DeBakey I and II variants involve the ascending aorta, whereas type 
B dissection (DeBakey III) involves the descending aorta only (1).  
  
6 
 
Acute AD (<14 days) is distinctfrom sub-acute (15–90 days), and chronic aortic dissection 
(>90days). 
 
Figure 1: Classifications of aortic dissection (Stanford and De Bakey).  
 
Epidemiology 
Up-to-date data on the epidemiology of AD are scarce. In the Oxford Vascular study, the 
incidence of AD is estimated at six per hundred thousand persons per year (2).  This 
incidence is higher in men than in women and increases with age (3). The prognosis is poorer 
in women, as a result of atypical presentation and delayed diagnosis. The most common risk 
factor associated with AD is hypertension, observed in 65–75% of individuals, mostly poorly 
controlled. In the IRAD registry, the mean age was 63 years; 65% were men (4). Other risk 
factors include pre-existing aortic diseases or aortic valve disease, family history of aortic 
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diseases, history of cardiac surgery, cigarette smoking, direct blunt chest trauma and use of 
intravenous drugs (e.g. cocaine and amphetamines). 
 
Clinical presentation and complications 
Chest pain is the most frequent symptom of acute AD. Abrupt onset of severe chest and/or 
back pain is the most typical feature. The pain may be sharp, ripping, tearing, knife-like, and 
typically different from other causes of chest pain; the abruptness of its onset is the most 
specific characteristic. The most common site of pain is the chest (80%), while back and 
abdominal pain are experienced in 40% and 25% of patients, respectively. Anterior chest pain 
is more commonly associated with Type A AD, whereas patients with Type B dissection 
present more frequently with pain in the back or abdomen. The clinical presentations of the 
two types of AD may frequently overlap. The pain may migrate from its point of origin to 
other sites, following the dissection path as it extends through the aorta. Although any pulse 
deficit may be as frequent as 30% in patients with Type A AD and 15% in those with Type B, 
overt lower limb ischaemia is rare (1).  
Aortic regurgitation may accompany 40–75% of cases with Type A AD (1,5). After acute 
aortic rupture, aortic regurgitation is the second most common cause of death in patients with 
AD. Patients with acute severe aortic regurgitation commonly present with heart failure and 
cardiogenic shock. 
Aortic regurgitation in AD includes dilation of the aortic root and annulus, tearing of the 
annulus or valve cusps, downward displacement of one cusp below the line of the valve 
closure, loss of support of the cusp, and physical interference in the closure of 
the aortic valve by an intimal flap.  
Pericardial tamponade may be observed in 20% of patients with acute Type A AD. This 
complication is associated with a doubling of mortality (6).  
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Myocardial ischaemia or infarction may be present in 10–15% of patients with AD and may 
result from aortic FL expansion, with subsequent compression or obliteration of coronary 
ostia or the propagation of the dissection process into the coronary tree (1). In the presence of 
a complete coronary obstruction, the ECG may show ST-segment elevation myocardial 
infarction. Also, myocardial ischaemia may be exacerbated by acute aortic regurgitation, 
hypertension or hypotension, and shock in patients with or without pre-existing coronary 
artery disease. This may explain the observation that approximately 10% of patients 
presenting with acute Type B AD have ECG signs of myocardial ischaemia. 
Overall, comparisons of the incidence of myocardial ischaemia and infarction between the 
series and between Types A and -B aortic dissection are challenged by the lack of a common 
definition. In addition, the ECG diagnosis of non-transmural ischaemia may be 
difficult in this patient population because of concomitant left ventricular hypertrophy, which 
may be encountered in approximately one-quarter of patients with AD. Both troponin 
elevation and ECG abnormalities, which may fluctuate over time, may mislead the physician 
to the diagnosis of acute coronary syndromes and delay proper diagnosis and management of 
acute AD. 
Congestive heart failure in the setting of AD is commonly related to aortic regurgitation. 
Although more common in Type A AD, heart failure may also be encountered in patients 
with Type B AD, suggesting additional aetiologies of heart failure, such as myocardial 
ischaemia, pre-existing diastolic dysfunction, or uncontrolled hypertension. Notably, in the 
setting of AD, patients with acute heart failure and cardiogenic shock present less frequently 
with the characteristic severe and abrupt chest pain, and this may delay diagnosis and 
treatment of AD. Hypotension and shock may result from aortic rupture, acute severe aortic 
regurgitation, extensive myocardial ischaemia, cardiac tamponade, preexisting left ventricular 
dysfunction, or major blood loss. 
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 Large pleural effusions resulting from aortic bleeding into the mediastinum and pleural space 
are rare, because these patients usually do not survive up to arrival at hospital. Smaller 
pleural effusions may be detected in 15–20% of patients with AD, with almost equal 
distribution between Type A and Type B patterns, and are believed to be mainly the result of 
an inflammatory process (1).  
Pulmonary complications of acute AD are rare, and include compression of the pulmonary 
artery and aortopulmonary fistula, leading to dyspnoea or unilateral pulmonary oedema, and 
acute aortic rupture into the lung with massive haemoptysis. 
Syncope is an important initial symptom of AD, occurring in approximately 15% of patients 
with Type A AD and in ,5% of those presenting with Type B. This feature is associated with 
an increased risk of in-hospital mortality because it is often related to life-threatening 
complications, such as cardiac tamponade or supra-aortic vessel dissection. In patients with 
suspected AD presenting with syncope, clinicians must therefore actively search for 
these complications (1). 
Neurological symptoms may often be dramatic and dominate the clinical picture,masking the 
underlying condition. They may result from cerebral malperfusion, hypotension, distal 
thromboembolism, or peripheral nerve compression. The frequency of neurological 
symptoms in AD ranges from 15–40%, and in half of the cases they may be transient. Acute 
paraplegia, due to spinal ischaemia caused by occlusion of spinal arteries, is infrequently 
observed and may be painless and mislead to the Leriche syndrome. The most 
recent IRAD report on Type A AD described an incidence of major brain injury (i.e. coma 
and stroke) in 10% and ischaemic spinal cord damage in 1.0% (7). Upper or lower limb 
ischaemic neuropathy, caused by a malperfusion of the subclavian or femoral territories, 
is observed in approximately 10% of cases. Hoarseness, due to compression of the left 
recurrent laryngeal nerve, is rare. 
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Mesenteric ischaemia occurs in 5% of patients with Type A AD (8). Adjacent structures and 
organs may become ischaemic as aortic branches are compromised, or may be affected by 
mechanical compression induced by the dissected aorta or aortic bleeding, leading to cardiac, 
neurological, pulmonary, visceral, and peripheral arterial complications. End-organ ischaemia 
may also result from the involvement of a major arterial orifice in the dissection 
process. The perfusion disturbance can be intermittent if caused by a dissection flap prolapse, 
or persistent in cases of obliteration of the organ arterial supply by FL expansion. Clinical 
manifestation is frequently insidious; the abdominal pain is often non-specific, 
patients may be painless in 40% of cases; consequently, the diagnosis is frequently too late to 
save the bowel and the patient. Therefore, it is essential to maintain a high degree of 
suspicion for mesenteric ischaemia in patients with acute AD and associated abdominal 
pain or increased lactate levels. The presence of mesenteric ischaemia deeply affects the 
management strategy and outcomes of patients with Type A AD; in the latest IRAD report, 
50% of patients with mesenteric malperfusion did not receive surgical therapy, while the 
corresponding proportion in patients without this complication was 12%.  
 
Laboratory testing 
In patients admitted to the hospital with chest pain and suspicion of AD, few laboratory tests 
are required for differential diagnosis or detection of complications. If D-dimers are elevated, 
the suspicion of AD is increased. Typically, the level of D-dimers is immediately very high, 
compared with other disorders in which the D-dimer level increases gradually. D-dimers 
yielded the highest diagnostic value during the first hour. If the D-dimers are negative, IMH 
and PAU may still be present; however, the advantage of the test is the increased alert for the 
differential diagnosis (9). Since AD affects the medial wall of the aorta, several biomarkers 
have been developed that relate to injury of the vascular endothelial or smooth muscle cells 
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(smooth muscle myosin), the vascular interstitium (calponin, matrix metalloproteinase 8), the 
elastic laminae (soluble elastin fragments) of the aorta, and signs of inflammation (tenascin-
C) or thrombosis, which are in part tested at the moment but have not yet entered the clinical 
arena. 
 
Diagnostic imaging in acute aortic dissection 
The main purpose of imaging in AAD is the comprehensive assessment of the entire aorta, 
including the aortic diameters, shape and extent of a dissection membrane, the involvement in 
a dissection process of the aortic valve, aortic branches, the relationship with adjacent 
structures, and the presence of mural thrombus (9).  
Computed tomography, MRI, and Transoesophageal echocardiography (TEE) are equally 
reliable for confirming or excluding the diagnosis of AAD. However, CT and MRI have to be 
considered superior to TEE for the assessment of AAD extension and branch involvement, as 
well as for the diagnosis of IMH, PAU, and traumatic aortic lesions. In turn, TEE using 
Doppler is superior for imaging flow across tears and identifying their locations. TEE may be 
of great interest in the very unstable patient, and can be used to monitor changes in-theatre 
and in post-operative intensive care. 
 
Diagnostic work-up 
The diagnostic work-up to confirm or to rule out AD is highly dependent on the a priori risk 
of this condition. The diagnostic tests can have different outputs according to the pre-test 
probability. In 2010, the ACC/American Heart Association (AHA) guidelines (10) 
proposed a risk assessment tool based on three groups of information - predisposing 
conditions, pain features, and clinical examination - and proposed a scoring system that 
considered the number of these groups that were involved, from 0  to 3 (Figure 2 ). The 
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IRAD reported the sensitivity of this approach, but a validation is not yet available (1). The 
presence of 0, 1, 2, or 3 groups of information is associated with increasing pre-test 
probability, which should be taken into account in the diagnostic approach to all AAS.  The 
diagnostic flow chart (Figure 3) proposed by current European Society of Cardiology (ESC) 
Guidelines on aortic disease (1) combines the pre-test probabilities (Figure 2) according to 
clinical data, and the laboratory and imaging tests, as should be done in clinical practice in 
emergency or chest pain units. 
Figure 2 Clinical data useful to assess the a priori probability of acute aortic syndrome 
Figure 3 Flowchart for decision-making based on pre-test sensitivity of acute aortic 
syndrome proposed by ESC Guidelines on aortic disease (1). 
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Treatment 
In type A Aortic dissection, surgery is the treatment of choice (1). Despite improvements 
in surgical and anaesthetic techniques, perioperative mortality (25%) and neurological 
complications (18%) remain high. However, surgery reduces 1-month mortality from 90% to 
30%. The advantage of surgery over conservative therapy is particularly obvious in the long-
term follow-up. Based on that evidence, all patients with TypeAAD should be sent for 
surgery; however, coma, shock secondary to pericardial tamponade, malperfusion of 
coronary or peripheral arteries, and stroke are important predictive factors for post-operative 
mortality. The superiority of surgery over conservative treatment has been reported, even in 
patients with unfavourable presentations and/or major comorbidities.  
Patients with uncomplicated Type B AD receive medical therapy to control pain, heart rate, 
and blood pressure, with close surveillance to identify signs of disease progression and/or 
malperfusion (1). Repetitive imaging is necessary, preferably with MRI or CT. 
 Thoracic endovascular aortic repair (TEVAR) is the treatment of choice in complicated acute 
Type B AD (1). The objectives of TEVAR are the closure of the ‘primary’ entry tear and of 
perforation sites in the descending aorta. The blood flowis redirected into the TL, leading to 
improved distal perfusion by its decompression. This mechanism may resolve malperfusion 
of visceral or peripheral arteries. Thrombosis of the FL will also be promoted, which is the 
initiation for aortic remodelling and stabilization. 
The term ‘complicated’ means persistent or recurrent pain, uncontrolled hypertension despite 
full medication, early aortic expansion, malperfusion, and signs of rupture (haemothorax, 
increasing periaortic and mediastinal haematoma). Additional factors, such as the FL 
diameter, the location of the primary entry site, and a retrograde component of the dissection 
into the aortic arch, are considered to significantly influence the patient’s prognosis (1). 
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Nowadays, surgery is rare in cases of complicated Type B AD, and has been replaced largely 
by endovascular therapy (1).  
For optimal repair of acute Type A AD in respect of long-term results—including risk of late 
death and late re-operation—the following points need to be addressed. In most cases of 
aortic insufficiency associated with acute Type A dissection, the aortic valve is essentially 
normal and can be preserved by applying an aortic valvesparing repair of the aortic root. 
Alternatively, given the emergency situation, aortic valve replacement can be performed. In 
any case, it is preferable to replace the aortic root if the dissection involves at least one sinus 
of Valsalva, rather than perform a supracoronary ascending aorta replacement only. The latter 
is associated with late dilation of the aortic sinuses and recurrence of aortic regurgitation, and 
requires a high-risk re-operation (1). Various techniques exist for re-implantion of the 
coronary ostia or preservation of the ostia of the coronary arteries. A current topic of debate 
is the extent of aortic repair; ascending aortic replacement or hemiarch replacement alone is 
technically easier and effectively closes the entry site but leave a large part of the diseased 
aorta untreated. Patients with visceral or renal malperfusion in acute Type A AD often have 
their primary entry tear in the descending aorta. These patients might profit from extended 
therapies, such as ‘frozen elephant trunk’ repair in order to close the primary entry tear and 
decompress the TL. The importance of intraoperative aortoscopy and of immediate post-
operative imaging—ideally in a hybrid suite—to reconfirm or exclude the effectiveness of 
therapy, is obvious. In contrast, more extensive repair, including graft replacement of the 
ascending aorta and aortic arch and integrated stent grafting of the descending aorta (‘frozen 
elephant trunk’) as a one-stage procedure is technically more challenging and prolongs the 
operation, with an increased risk of neurological complications, but offers the advantage of a 
complete repair, with a low likelihood of late re-intervention (1). If the dissection progresses 
into the supra-aortic branches, rather than the classic ‘island’ technique, end-to-end grafting 
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of all supra-aortic vessels may be considered, using individual grafts from the arch prosthesis. 
There is still controversy over whether surgery should be performed in patients with TypeA 
AD presenting with neurological deficits or coma. Although commonly associated with a 
poor post-operative prognosis, recovery has been reported when rapid brain reperfusion is 
achieved, especially if the time between symptom onset and arrival at the operating room is < 
5 hours. 
One major factor influencing the operative outcome is the presence of mesenteric 
malperfusion at presentation. Malperfusion syndrome occurs in up to 30% of patients with 
acute AD. Visceral organ and/or limb ischaemia is caused by dynamic compression of 
the TL, due to high-pressure accumulation in the FL as the result of large proximal inflow 
into the thoracic aortic FL and insufficient outflow in the distal aorta. Malperfusionmay also 
be caused by extension of the intimal flap into the organ/peripheral arteries, resulting in 
static ‘stenosis-like’ obstruction. In most cases, malperfusion is caused by a combination of 
dynamic and static obstruction; therefore, surgical/hybrid treatment should be considered for 
patients with organ malperfusion (1). 
As regards Type B AAS, future studies will have to better clarify whether uncomplicated 
forms benefit from immediate TEVAR treatment. 
 
Key issues in the contemporary management: diagnostic delay and 
misdiagnosis 
AAS may be rapidly fatal without early diagnosis and appropriate management. Symptoms, 
signs, electrocardiograms (ECGs), and chest X-rays lack sensitivity and specificity. 
Diagnosis is therefore not immediate; definitive confirmatory investigation may not available 
in the emergency room (ER), and the varied presentation allows the diagnosis to be missed, 
misdiagnosed, or overlooked in up to 40% of cases, sometimes only being established at post-
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mortem (11,12). Acute type A dissection is highly lethal, but a rapid diagnosis may allow 
life-saving surgical repair. Untreated mortality may approximate 1% to 2%/h following 
symptom onset with the majority of patients succumbing within 30 days. Surgical repair 
transforms the high mortality risk to a greater than 70% survival chance in the short term. 
This survival advantage of surgery continues in the longer term with outcomes vastly 
superior to those achieved by conservative management (12).  
For all AAS, reduction in overall patient mortality might be best achieved by shortening the 
time from symptoms to treatment. Notwithstanding several recommendations and guidelines, 
the evidence suggests that definitive management is delayed for several hours while 
diagnostic evaluation is completed (12). Approximately 75% of patients with acute dissection 
have their initial diagnosis made in a non specialist hospital (13). The time from initial 
symptoms to hospital presentation is approximately 1 to 2 h, but the time to diagnosis varies 
considerably. Fifty percent of patients have a time to diagnosis of > 6 h in Europe and >15 h 
in the U.S.; 75% of patients have diagnostic times > 3 to 4 h (13). In type A dissection, the 
time duration between presentation and definitive management is >12 h in the majority of 
patients and has been reported as being >24 h in 20% to 50% in some series (14). Patients 
presenting with atypical symptoms are at increased risk of in-hospital mortality, which may 
be related to diagnostic delay, prolonging the institution of treatments that may affect the 
disease’s natural history, particularly dissection propagation (12). Delays in instigating blood 
pressure control in type B dissection may be > 24 h after the initiating event, a period during 
which the natural history of the dissection is defined. Therefore, the prognostic significance 
of accelerating diagnosis is evident. 
Diagnostic delay is exacerbated by nonclassical presentations that do not evoke clinical 
suspicion such as painless malperfusion phenomena, dyspnea due to heart failure or pleural 
effusion, acute coronary syndrome– like ECG, limb ischemia, or abdominal pain, all of which 
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are associated with longer in-hospital diagnostic times (15). The challenge is therefore to 
accurately diagnose the condition as early as possible. The primary presentation of AAD to 
the ER is most commonly an elderly male, with hypertension and sudden onset chest pain, 
and the much more common acute coronary syndrome is an important differential diagnosis 
(12). In addition, the recent introduction of high sensitivity troponin (Tn) assay has 
determined an increase of the number of patients with abnormal Tn levels also in absence of a 
final diagnosis of myocardial infarction (16); therefore, an ACS misdiagnosis in patients with 
AAS may be even more frequent in the contemporary era. Any lack of suspicion of AAD will 
fail to trigger investigation, delaying diagnosis. In the absence of a rapid, accurate, and 
readily available diagnostic test, the current diagnosis of AAD requires definitive imaging 
such as computed tomography (CT), transesophageal echocardiography (TEE), or magnetic 
resonance imaging (MRI) (1),  but the use of each investigation is based on an index of 
clinical suspicion, and each incurs a further logistical delay in patient management (12). 
Myocardial ischemia has the diagnostic advantages of the ECG and troponin estimation, 
allowing risk stratification and emergency treatment.  AAS have no such rapidly available 
diagnostic tools (12).  
However, the higher and early mortality of these conditions appeals for improved physician 
awareness of possible presentations of AAS, in order to reduce diagnostic times, 
misdiagnosis, inappropriate therapy, and improve outcome.  
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PART I  TROPONIN T ELEVATION IN ACUTE AORTIC 
SYNDROMES: FREQUENCY AND IMPACT ON DIAGNOSTIC DELAY 
AND MISDIAGNOSIS 
 
Background 
Acute aortic syndromes (AAS) are a life-threatening cardiovascular emergency with a 
mortality rate of up to 1%/hour (17); hence, prompt diagnosis and initiation of appropriate 
management are of paramount importance. However, AAS presentation often mimics acute 
coronary syndromes (ACS) leading to a number of imaging and laboratory investigations, 
including serum troponin evaluation, which might be expected to impact the promptness of 
treatment.  Despite troponin assay being part of the diagnostic work up in many cases of 
AAS, little is known about frequency and clinical implications of troponin elevation in this 
condition. The available studies addressing this issue are small in size and lead to conflicting 
results (18-20). Regrettably, the largest available AAS registry (IRAD) has not focused on 
this topic (4,21). In particular, it is unknown whether the finding of elevated troponin in these 
AAS patients may initially mislead into considering the patient a possible ACS case, which 
might have potentially deleterious consequences in terms of delaying surgical treatment, 
and/or exposing the patient to unnecessary (or potentially harmful) therapies and procedures. 
 
Aims  
Using data from a prospective metropolitan network AAS registry, our study was aimed to 
describe the frequency of troponin elevation, to define the clinical and instrumental profile of 
patients with this finding, and to explore the impact on the time to diagnosis and on outcome. 
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Methods 
Setting and Patients 
Our registry (AESA, Archivio Elettronico Sindromi Aortiche acute) includes data from all 
consecutive patients referred to our Institution between 2000 and 2013 who received a final 
diagnosis of spontaneous AAS. The S. Orsola-Malpighi University Hospital is the referral 
centre for AAS treatment in a metropolitan hospital network that covers Bologna and its 
surroundings (catchment area approximately 1.000.000 people). The database contains 
comprehensive demographical, clinical, instrumental, laboratory findings of the patients at 
first hospital contact (either spoke or hub), as well as treatment and outcome details. The 
following relevant diagnostic time intervals are also recorded: 1) symptoms onset to 
presentation at any hospital; 2) hospital presentation to final AAS diagnosis; 3) global 
diagnostic delay (symptoms onset to final AAS diagnosis at any hospital); surgical delay 
(final diagnosis to entry in the operating room).  As in IRAD registry, data concerning the 
different delays were prospectively collected during the initial phases of hospitalization (21).  
The “time of final diagnosis” was defined as the time when the first demonstration of the 
aortic lesion was documented on an imaging examination and recorded. 
Patients with symptoms onset >14 days at hospital presentation were not included in the 
registry. AAS (aortic dissection, penetrating ulcer and intramural hematoma) were defined 
according to the Stanford classification (22).    
In all cases (presenting at either a hub or a spoke centre) the diagnosis was confirmed by a 
multidisciplinary team that included a cardiologist, heart surgeon, and cardiovascular 
radiologist.  
The local ethics committee approved the study.  
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Definitions 
Cardiac troponin testing was performed according to the standard protocol used in chest pain 
units  (blood samples taken at presentation and after 3, 6 and 12 hours, or until a correct 
diagnosis of AAS was reached). Until 2010 standard cardiac troponin T (cTnT) test was used  
(Troponin T Elecsys, fourth generation; Roche Diagnostics GmbH, Mannheim, Germany), 
which has since been replaced by high sensitivity (HS)-cTnT assay (Troponin T HS Elecsys; 
Roche Diagnostics GmbH, Mannheim, Germany). For the standard cTnT test the analytical 
limit of detection (LoD) and the URL are both 10 ng/L, and the 10% CV cut-off value is 30 
ng/L. The diagnosis of troponin positivity using standard cTnT testing was made in the 
presence of at least one value of cTnT > 30 ng/L (10% CV cut-off). 
The HS-cTnT assay has an analytical LoD of 3 ng/L, the URL is 14 ng/L and the 10% CV 
cut-off is 13 ng/L. When HS-cTnT was used, the diagnosis of troponin positivity was made in 
the presence of at least one value of HS-cTnT > 14 ng/L (URL).  
According to current guidelines, electrocardiogram (ECG) was considered to be acute 
coronary syndrome (ACS)-like in the presence of ≥ 1 of the following characteristics: 1) ST-
segment elevation in two contiguous leads with the cut-point ≥ 0.1 mV in all leads other than 
leads V2-V3, where the cut- point is ≥ 0.2 mV; 2) horizontal or down-sloping ST-segment 
depression ≥ 0.05 mV in two contiguous leads; 3) T-wave inversion ≥ 0.1 mV in two 
contiguous leads (23). 
Shock was defined as sustained hypotension (systolic blood pressure <90 mm Hg for >30 
minutes), accompanied by clinical signs of peripheral/cerebral hypoperfusion (24). We used 
standard definition of cardiac tamponade (25).   
Severe and moderate-to-severe aortic regurgitation at transthoracic/transesophageal 
echocardiography were considered hemodynamically significant. Pleural effusion was 
diagnosed by chest x-ray or CT scan. Pericardial effusion was diagnosed by 
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transthoracic/transesophageal echocardiogram, CT scan, or magnetic resonance imaging. 
Periaortic hematoma was diagnosed by transthoracic/transesophageal echocardiogram, CT, or 
magnetic resonance imaging (26).   
 
Study design and statistical analysis  
To explore the clinical impact of troponin and other possible determinants the following 
endpoints were considered: in-hospital mortality, in-hospital diagnostic delay, and a 
composite endpoint represented by the combination of in-hospital delay, coronary 
angiography, antithrombotic therapy (the latter two representing unnecessary/deleterious  
consequences of an initial diagnosis of ACS). To identify particularly long diagnostic times 
we used 75
th
 percentile of in-hospital delay as cut-off (15).  
To evaluate the possible impact of a positive troponin finding on in-hospital delay and on the 
composite endpoint, the overall registry population was assessed in a logistic regression 
analysis and patients with positive troponin were compared to patients with negative or 
unavailable troponin (i.e., in whom management could have not been possibly influenced by 
the notion of troponin positivity).   
To identify predictors of in-hospital mortality and of surgical mortality in patients with 
Stanford A, we considered only the subgroup tested for troponin; patients with positive were 
compared to patients with negative assay. 
Categorical data were expressed as proportions, and continuous variables reported as 
mean SD or median and interquartile range (IQR), as appropriate. Chi-square test for 
categorical variables was used to compare groups. Two-tailed Student t test was used to 
compare normally distributed continuous variables.  Comparison of non-normally distributed 
variables was performed using the Mann-Whitney U test.  
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Non correlated variables with p < 0.2 at the univariable analyses were included in the 
multivariable analysis. Model discrimination was assessed by c-statistic, and model 
calibration was assessed by Hosmer-Lemeshow statistic.  
A p value <0.05 in the two-tailed tests was considered significant. All analyses were 
performed with the STATA/SE 12.1 software for Windows (StataCorp LP, College Station, 
Texas, USA). 
 
Results 
Study Population  
During the study period 398 patients received a final diagnosis of spontaneous AAS 
(Stanford type A 258; Stanford type B 140) and were entered into the AESA Registry. Their 
main characteristics are reported in Tables 1A and 1B. Presentation with cardiac tamponade, 
shock, significant aortic regurgitation, and ACS-like ECG findings was more common in 
patients with type A AAS. On the other hand, patients with type B AAS had higher systolic 
blood pressure and more frequently complained of back or abdominal pain. 
Routinely performed troponin test results were available for 248 patients (62%) including 171 
(69%) tested with the standard troponin assay and 77 (31%) with HS test. Epidemiological, 
clinical, instrumental and outcome findings of the patients with/without troponin availability 
were comparable (Supplementary Tables 1A and 1B, Supplementary Tables 2A and 2B).  
 
Frequency and profile of patients with troponin T positivity 
The overall frequency of troponin T positivity was 28% (70/248), with no difference between 
type A  (50/167, 30%) and type B (20/81, 25%, p = 0.47). The proportion of patients with 
positive troponin T was higher among those tested by HS assay (42 of 77, 54% vs. 28 of 171, 
16%, p = 0.001) (Table 2).   
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Baseline clinical and instrumental characteristics of patients according to Troponin T results 
are shown in Tables 3A and 3B. Troponin positivity was more frequently associated with 
ACS-like ECG findings.  
 
Risk factors for diagnostic delay and misdiagnosis 
In the entire registry median global diagnostic delay was 307 (Q1-Q3, 108 - 900) minutes. 
Median pre-hospital and in-hospital delays were 90 (Q1-Q3, 50 - 210) minutes and 166 (Q1-
Q3, 90-353) minutes, respectively. Regarding in-hospital diagnostic delay, 297 patients had a 
diagnostic time < 75
th
 percentile (corresponding to 353 minutes) while 101 had a longer 
delay. With respect to troponin results, in-hospital diagnostic delay was 210 (Q1-Q3, 103-
829) in patients with evidence of troponin positivity, and 177 (Q1-Q3, 100-342)  in patients 
with  negative troponin values (p = 0.042). 
Risk factors for late in-hospital diagnosis (> 75
th
 percentile, 353 min) are reported in Table 4. 
By multivariable analysis troponin positivity was significantly associated with an 
approximately twofold increased risk of longer in-hospital delay (OR 1.92, 95% CI 1.05-
3.52, p = 0.03), compared to negative/unavailable troponin. Excess risk for in-hospital 
diagnostic delay was also related to dyspnoea and pleural effusion, while systolic blood 
pressure < 90 mmHg and back pain were associated with an earlier recognition of AAS. The 
risk predicted by the model was well correlated with the observed events (76.4 % of correct 
classification, c-statistic = 0.71, Hosmer-Lemeshow goodness-of-fit p = 0.63).   
Risk factors for the composite endpoint of late in-hospital diagnosis and inappropriate 
treatments due to a misdiagnosis of ACS  are reported in Table 5. By multivariable analysis 
ACS-like ECG was associated with a twofold increased risk (OR 2.12, 95% CI 1.26-3.59, p = 
0.005). Excess risk was also related to dyspnoea and pleural effusion and syncope, while 
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systolic blood pressure < 90 mmHg ,pulse deficit, and back pain were associated with a 
reduced risk.   
The effect of the interplay between troponin data and ECG findings on diagnostic delay and 
inappropriate treatments are summarized in Figure 1. The combination of positive troponin 
and ACS-like ECG resulted in a significantly increased risk of both late in-hospital 
recognition (OR 2.34, 95% CI 1.05-5.18, p = 0.03), and of composite endpoint (in-hospital 
delay, coronary angiography, antithrombotic therapy) (OR 2.48, 95% CI 1.12-5.54, p = 0.02).  
 
Risk factors for mortality  
Considering the overall population of the Registry, 85.6 % (221/258) of type A patients 
underwent surgical treatment. In the remaining 37 cases surgery was not performed due to 
advanced age, comorbidity, patient refusal, or death. Sixty-six of 140 type B patients 
underwent endovascular (n = 51) or surgical (n = 15) treatment due to thoracic/abdominal 
underperfusion, uncontrolled hypertension, or impending rupture of the false lumen. 
Surgical mortality was 20.4% (45/221) in type A and 15.2% (10/66) in type B. Global in-
hospital mortality was 26.3% (68 of 258) in type A and 13.6% (19 of 140) in type B.  
In the subgroup of 248 patients tested for troponin the association between this biomarker and 
mortality was assessed in conjunction with other plausible risk factors (Table 6 and 7).  Table 
6 shows the results of univariable and multivariable analysis of risk factors for global in-
hospital mortality. Pleural effusion, age, shock, dyspnoea, Stanford type A, and ACS-like 
ECG abnormalities were associated with increased in-hospital mortality, whereas only pleural 
effusion, age, dyspnoea, and shock were confirmed as independent predictors after 
multivariable analysis. The risk predicted by the model was well correlated with the observed 
events (79.7 % of correct classification, c-statistic = 0.74, Hosmer-Lemeshow goodness-of-fit 
p = 0.482).  Of note, frequency of troponin positivity was not significantly different between 
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patients who survived and those who died (26% vs. 35.7%, p = 0.21, Supplementary Table 5) 
(unadjusted OR 1.63, 95% CI 0.86-3.10, p = 0.13).  
Univariable and multivariable analysis of risk factors for in-hospital mortality of Type A 
patients who underwent surgical intervention are shown in Table 7. Only ACS-like ECG, 
pleural effusion and age were independently associated with surgical mortality. In particular, 
troponin positivity (either standard or HS) was not an incremental risk factor .  
 
 
DISCUSSION  
This is the first study to focus on plasma troponin evaluation -including HS troponin assay- in 
a large cohort of patients with AAS. The main results of our analysis are that troponin is 
abnormal in a large proportion of cases (up to 54% using the HS assay), which may lead to a 
relevant in-hospital diagnostic delay. 
The study population of our series is comparable to that of the IRAD registry; in particular 
with regard to age (mean value in our registry 66.7 yrs compared to 63.1), male prevalence 
(67% vs. 65%), and ratio between Stanford types A and B (1.84 vs.1.65). Frequency and 
distribution of signs and symptoms at presentation was also similar to the IRAD registry (27). 
Notably, the frequency of findings classically considered “pathognomonic” of AAS (i.e., 
migratory pain, pain plus pulse deficit or pain plus cerebrovascular accident) was relatively 
rare (Table 1A), and patients with type A AAS more frequently showed hypotension, shock, 
pericardial effusion, aortic regurgitation. Plaque ruptures / ulcerations were more common in 
Type B.  As in IRAD, about one fourth of the patients had an ACS-like ECG at presentation 
(27).  
Troponin positivity was found in 28% of our population, ranging from 16% using the 
standard troponin assay, to 54% using the more recent HS assay (Table 2). The small 
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previous studies that included information regarding standard troponin in AAS, reported a 
positivity ranging from 11% (19) to 23% (18). The high prevalence of positive HS troponin 
in our study cannot be compared to any published series.  
Although our study was not aimed to investigate the pathophysiology of troponin release, our 
registry offers some insights into the potential mechanisms. Since troponin is not a 
constituent of the aortic wall (28), the abnormal troponin increase during AAS is reasonably 
the consequence of myocardial injury.  Notably, troponin elevation was more frequently 
associated with ACS-like ECG abnormalities (41,4% vs. 21.9 %, p = 0.003). However only 
9/70 patients (13%) with positive troponin presented with a typical ST-elevation suggestive 
of true myocardial infarction, initially leading the patient to the cath lab for a primary 
angioplasty in 3 patients and to intense antithrombotic therapy in 6 patients (Supplementary 
Table 4).  More in general, 4 out of 10 patients studied with TOE had a clear anatomic 
obstruction of at least one coronary artery due to coronary dissection (2 patients) or diastolic 
apposition of the flap to the ostium (2 patients). In the remaining cases the mechanism, albeit 
undefined, is probably multifactorial including acute pressure overload, acute volume 
overload (aortic insufficiency) and shock in patients with or without pre-existing coronary 
disease (Figure 2). Notably, although more frequent in type A, troponin elevation occurred 
also in type B AAS independently of age, gender and clinical history of the patients (Table 
3).  
One of the main findings of our study is the association between troponin positivity and 
delayed diagnostic time. Indeed, patients with troponin elevation reach the correct diagnosis 
of AAS more than two hours later (median values) than patients without this finding, and this 
extra time was predominantly due to the in-hospital phase (Table 3B). This “delay effect” 
was amplified in case of concomitant association with ACS-like ECG abnormalities (Figure 
1). Notably, the concomitant presence of troponin elevation and ACS-like ECG abnormalities 
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also increases the probability of  inappropriate management (coronary angiography or intense 
antithrombotic  treatment) due to a misdiagnosis of ACS. In addition to troponin positivity, 
pleural effusion and dyspnoea as presentation symptom were the other independent variables 
associated with an incremental delay in our study. Probably these findings at presentation 
lead the physician to embrace an immediate diagnosis of ACS (or pneumonia-associated 
pleuritis). Comparison with the largest study (21) on the causes of the diagnostic delay is not 
immediate, since the IRAD Registry considered only patients with Stanford type A, and it did 
not include troponin in the predictive model of the delay.  Differently from IRAD, in our 
registry neither female gender nor pain characteristics at presentation had a clear confounding 
or facilitating effect on diagnosis. Differences in sample size, geographic distribution and cut-
off values adpopted for delays may explain the differences between the two registries.  
In-hospital mortality of our patients (overall = 21,8%, surgically treated type A = 20,4%, 
medically treated type A = 62,1%, type B = 12,2%) was similar to that observed in the IRAD 
registry (27). In keeping with IRAD findings, age, shock (and pleural effusion and dyspnoea 
in our study) were confirmed as independent predictors of in-hospital mortality.  
Despite the strong effect on diagnostic delay and on potentially catastrophic treatments 
(Figure 1), troponin positivity (either standard or HS) was not a statistically significant 
incremental risk factor for in-hospital mortality in medically as well as surgically treated 
patients. It should be emphasized, however, that ACS-like ECG abnormalities were 
associated with increased risk of in-hospital mortality, especially for type A surgically treated 
patients. Therefore it could be speculated that only a significant level of myocardial damage 
(relevant enough to determine ischaemic ECG changes) is able to affect short-term outcome. 
Further analyses are needed to explore a possible prognostic effect of troponin positivity on 
long-term outcome. 
 
  
28 
 
LIMITATIONS 
 Our prospective registry refers to a single hub center operating in a rather densely 
populated urban area with a long-lasting hub & spoke organization. So the findings regarding 
hospital arrival times cannot be generalized to more challenging geographic settings. 
Unavoidably, this registry included only patients who reached a final diagnosis of AAS and 
could not consider (or include) the patients that never received a diagnosis of AAS, or had a 
post-mortem diagnosis. In our registry, encompassing a 13-year period, troponin assay was 
performed more often in recent cases. However the profile of patients with/without available 
troponin are strictly comparable regarding epidemiological and morphologic characteristics, 
use of imaging techniques and outcome (Supplementary Tables 1A and 1B). Although 
troponin assay was available only in 60% of the overall population, we decided to investigate 
the effect of troponin on diagnostic delay and misdiagnosis by comparing patients with 
positive troponin with the remaining patients (negative or unavailable assay), assuming that 
only the knowledge of positive result can lead the physician towards a misdiagnosis of ACS.  
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Table 1.A Baseline clinical characteristics in overall study population and according to Stanford type. 
 
VARIABLE 
 
OVERALL 
(n=398) 
 
Type A 
(n=258) 
 
Type B 
(n=140) 
 
P  
value 
Patients’ characteristics 
Age (yrs), mean ± SD 66,7 ± 13,3 66,5 ± 13,4 66,9 ± 13,7 0.476 
Men 266 (66,8%) 166 (64,3%) 100 (71,4%) 0.186 
Hypertension (history) 304 (76,4%) 193 (74,8%) 111 (79,3%) 0.378 
Anti-hypertensive therapy 263 (66,1%) 169 (65,5%) 94 (67,1%) 0.827 
Marfan syndrome 7 (2,1%) 4 (1,8%) 3 (2,5%) 0,977 
Bicuspid aortic valve  9 (2,3%) 7(2,7%) 2 (1,4%)  0.638 
Aortic coarctation 1 (0,3%) 1 (4,5%) 0 (0%) 0,756 
Known thoracic aortic aneurysm 20 (5,0%) 13 (5,0%) 7 (5,0%) 0.823 
Re-dissection 6 (1,5%) 3 (1,4%) 3 (2,1%) 0.737 
Previous stroke 22 (5,5%) 15 (5,8%) 7 (5,0%) 0.913 
Coronary artery disease (history) 28 (7,0%) 20 (7,7%) 8 (5,7%) 0.580 
Clinical features at presentation 
Systolic blood pressure (mm Hg) 145 ± 42  
(389/398) 
134 ± 38 
(253/258) 
168 ± 39 
(136/140)  
<0.001 
Systolic blood pressure ≤ 90 mm Hg 68/389 (17,5%) 58/253 (22,9%) 10/136 (7,3%) <0.001 
Systolic blood pressure > 160 mm Hg 125/389 
(32,1%) 
58/253 (22,9%) 67/136 
(49,3%) 
<0.001 
Back pain 194 (48,7%) 96 (37,2%) 98 (70,0%) <0.001 
Chest pain  261 (65,6%) 187 (72,5%) 74 (52,8%) <0.001 
Migratory pain  51 (12,8%) 31 (12,0%) 20 (14,3%) 0.624 
Abdominal pain 110 (27,6%) 55 (21,3%) 55 (39,3%) <0.001 
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Pain plus syncope 34 (8,5%) 30 (11,6%) 4 (2,8%) 0,005 
Pain plus shock 44 (11,1%) 41 (15,9%) 3 (2,1%) <0.001 
Pain plus cerebrovascular accident 12 (3,0%) 11 (4,3%) 1 (0,8%) 0,095 
Pain plus paraplegia 10 (2,5%) 9 (3,5%) 1 (0,8%) 0,176 
Peripheral pulse deficits 91 (22,8%) 63 (24,4%) 28 (20,0%) 0.380 
Dyspnea 58 (14,6%) 34 (13,2%) 24 (17,1%) 0.357 
Autonomic symptoms 155 (38,9%) 118 (45,7%) 37 (26,4%) <0.001 
Shock within 12 of admission 57 (14,3%) 51 (19,8%) 6 (4,2%) <0.001 
ACS-like ECG + chest pain 72 (18,1%) 58 (22,5%) 14 (10,0%) 0.003 
Disease complications 
Cardiac tamponade 38 (9,5%) 38 (14,7%) 0 (0%) <0.001 
Pleural effusion 99 (24,9%) 56 (21,7%) 43 (30,7%) 0.062 
Pericardial effusion 123 (30,9%) 109 (42,2%) 14 (10,0%) <0,001 
Periaortic effusion 63 (15,8%) 34 (13,2%) 29 (20,7%) 0,068 
Moderate/severe aortic regurgitation 106 (26,6%) 96 (43,4%) 10 (7,1%) <0.001 
Coronary ostia involvement 22 (5,5%) 22 (8,5%) 0 (0%) <0.001 
Presence of intramural hematoma 117 (29,4%) 64 (24,8%) 53 (37,8%) 0.009 
Presence of plaque rupture/ulceration 25 (6,3%) 10 (3,9%) 15 (10,7%) 0.014 
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Table 1.B Instrumental examinations, treatment and outcome in overall study population and 
according to Stanford type. 
 
VARIABLE 
 
OVERALL 
(n=398) 
 
Type A 
(n=258) 
 
Type B 
(n=140) 
 
P  
value 
Instrumental examinations 
Computed tomography 372 (93,5%) 234 (90,7%) 138 (98,6%) 0.005 
Transesophageal echocardiography 87 (21,8%) 66 (25,6%) 21 (15,0%) 0.021 
Transthoracic echocardiography 222 (55,8%) 137 (53,1%) 85 (60,7%) 0.176 
Chest radiograph 237 (59,5%) 138 (53,5%) 99 (70,7%) 0.001 
Abdominal ultrasound 78 (19,6%) 39 (15,1%) 39 (27,8%) 0.003 
Magnetic resonance imaging 20 (5,0%) 4 (1,6%) 16 (11,4%) <0.001 
Angiography 42 (10,6%) 24 (9,3%) 18 (12,8%) 0.352 
ACS-like electrocardiogram 102 (25,6%) 75 (29,1%) 27 (19,3%) 0.044 
Troponin positivity 70/248 (28,2%) 50/167 (29,9%) 20/81 (24,7%) 0.477 
Treatment 
Surgery/Endovascular  287 (72,1%) 221 (85,6%) 66 (47,1%) <0.001 
Only medical treatment 111 (27,9%) 37 (14,3%) 74 (52,8%) 
Outcome 
In-h death 87 (21,8%) 68 (26,3%) 19 (13,6%) 0,005 
In-h death of patients surgically treated  55 (13,8%) 45/221 (20,4%) 10/66 (15,2%) 0,444 
In-h death of patients treated with 
medical therapy 
32 (8,0%) 23/37 (62,1%) 9/74 (12,2%) 0,001 
 
 
ACS indicates acute coronary syndromes; in-h, in-hospital.  
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Table 2. Baseline characteristics and outcomes of Acute Aortic Dissection patients with Troponin 
positive vs. negative values according to different assays.   
 
 
 
 
 
Abbreviations: cTn: cardiac troponin; HS : high sensitivity; ACS: acute coronary syndrome; IQR : 
interquartile range 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Overall 
n= 248 
Standard cTn 
n = 171 
HS-cTn 
n = 77 
 cTn - 
 
n =  178 
(72%) 
cTn + 
 
n = 70 
(28%) 
p Standard 
cTn - 
n = 143 
(84%) 
Standard 
cTn + 
n = 28 
(16%) 
p HS-cTn - 
 
n = 35 
(46%) 
HS-cTn    + 
 
n = 42 
(54%) 
p 
Age 
 
67 ± 12 69 ± 14 0,16 66 ± 14 68 ±  12 0,23 65 ± 12 69 ± 13 0,14 
Male gender 126 
(71%) 
40 
(57%) 
0,05 104 
(73%) 
15                        
( 54%) 
0,07 22 
(63%) 
25 
(60%) 
0,94 
Stanford A 117 
(66%) 
50 
(71%) 
0,47 94 
(66%) 
20 
(71%) 
0,71 23 
(66%) 
30 
(70%) 
0,77 
ACS-like  
ECG findings 
39 
(21,9%) 
29 
(41,4%) 
0,003 34 
(24%) 
13 
(46%) 
0,02 5 
(7%) 
16 
(38%) 
0,03 
In-hospital 
mortality 
35 
(19,7%) 
20 
(28,6%) 
0,17 31 
(22%) 
12 
(43%) 
0,03 4 
(11%) 
8 
(19%) 
0,54 
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Table 3.A Baseline characteristics of patients according to troponin test results.  
 
VARIABLE 
OVERALL 
 
(n=248) 
Abnormal 
Troponin T values 
(n=70) 
Normal Troponin 
T values 
(n=178) 
 
P 
value 
Patients’ characteristics 
Age (yrs), mean ± SD 68 ± 13 69 ± 14 67 ± 12 0.261 
Stanford A 167 (67,3%) 50 (71,4%) 117 (65,7%) 0.477 
Men 166 (66,9%) 40 (57,1%) 126 (70,8%) 0.057 
Hypertension (history) 191 (77,0%) 51 (72,5%) 140 (78,6%) 0.419 
Anti-hypertensive therapy 166 (66,9%) 41 (58,6%) 125 (70,2%) 0.108 
Marfan syndrome 3 (1,2%) 1 (1,4%) 2 (1,1%) 0.654 
Bicuspid aortic valve  7 (2,8%) 2 (2,9%) 5 (2,8%) 0.685 
Aortic coarctation 1 (0,4%) 0 (0%) 1 (0,6%) 0.628 
Known thoracic aortic 
aneurysm 
17 (6,8%) 3 (4,3%) 14 (7,9%) 0.468 
Known abdominal aortic 
aneurysm 
15 (6,0%) 3 (4,3%) 12 (6,7%) 0.664 
Previous ascending aorta 
and/or valve surgery 
5 (2,0%) 3 (4,3%) 2 (1,1%) 0.274 
Previous stroke 15 (6,0%) 4 (5,7%) 11 (6,2%) 0.875 
Coronary artery disease 
(history) 
19 (7,7%) 7 (10,0%) 12 (6,7%) 0.546 
Clinical features at presentation 
Systolic blood pressure (mm 
Hg) 
146 ± 42 
(245/248) 
142 ± 41 
(70/71) 
148 ± 42 
(175/178) 
0.309 
Systolic blood pressure ≤ 90 43/245 (17,6%) 17/70(24,3%) 26/175 (14,8%) 0.983 
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mm Hg 
Systolic blood pressure > 
160 mm Hg 
82/245 (33,6%) 23/70 (32,8%) 59/175 (33,7%) 0.915 
Back pain 116 (46,8%) 32 (45,7%) 84 (47,2%) 0.945 
Chest pain  186 (75,0%) 59 (84,3%) 127 (71,3%) 0.051 
Migratory pain  32 (12,9%) 8 (11,4%) 24 (13,5%) 0.823 
Abdominal pain 72 (29,0%) 15 (21,4%) 57 (32,0%) 0.134 
Pain plus syncope 27 (10,9%) 11 (15,7%) 16 (9,0%) 0.192 
Pain plus shock 28 (11,3%) 11 (15,7%) 17 (9,6%) 0.247 
Pain plus paraplegia 4 (1,6%) 2 (2,9%) 2 (1,1%) 0.678 
Pain plus aortic regurgitation 66 (26,6%) 15 (21,4%) 51 (28,6%) 0.318 
Pain plus pulse deficit 48 (19,3%) 15 (21,4%) 33 (18,5%) 0.734 
Pain plus cerebrovascular 
accident 
9 (3,6%) 3 (4,3%) 6 (3,4%) 0.976 
Pain in other sites 46 (18,5%) 12 (17,1%) 34 (19,1%) 0.861 
No pain  16 (6,5%) 7 (10,0%) 9 (5,1%) 0.255 
Peripheral pulse deficits 54 (21,8%) 17 (24,3%) 37 (20,8%) 0.667 
Dyspnea 48 (19,3%) 13 (18,6%) 22 (12,3%) 0.288 
Syncope 37 (14,9%) 15 (21,4%) 22 (12,3%) 0.108 
Autonomic symptoms 105 (42,3%) 27 (38,6%) 78 (43,8%) 0.542 
Paraplegia 6 (2,4%) 2 (2,9%) 4 (2,2%) 0.859 
Shock within 12 of 
admission 
37 (14,9%) 15 (21,4%) 22 (12,3%) 0.108 
Lower limbs pain alone 5 (2,0%) 1 (1,4%) 4 (2,2%) 0.929 
Neurological symptoms 
alone 
10 (4,0%) 3 (4,3%) 7 (3,9%) 0.817 
Cardiac tamponade 30 (12,1%) 8 (11,4%) 22 (12,3%) 0.989 
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Pleural effusion 62 (25,0%) 21 (30,0%) 41 (23,0%) 0.328 
Pericardial effusion 88 (35,5%) 26 (37,1%) 62 (34,8%) 0.845 
Periaortic effusion 41 (16,5%) 9 (12,8%) 32 (18,0%) 0.431 
Moderate/severe aortic 
regurgitation 
70 (28,2%) 18 (25,7%) 52 (29,2%) 0.693 
Coronary ostia involvment 13 (5,2%) 5 (7,1%) 8 (4,5%) 0.599 
Presence of intramural 
hematoma 
76 (30,6%) 24 (34,3%) 52 (29,2%) 0.531 
Presence of plaque 
rupture/ulceration 
18 (7,3%) 5 (7,1%) 13 (7,3%) 0.820 
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Table 3.B Instrumental examinations, treatment and outcome according to troponin test results.  
 
 
 
VARIABLE 
OVERALL 
 
(n=248) 
Abnormal 
Troponin T values 
(n=70) 
Normal Troponin 
T values 
(n=178) 
 
P 
value 
Instrumental examinations 
Computed tomography 232 (93,5%) 64 (91,4%) 168 (94,4%) 0.572 
Transesophageal 
echocardiography 
55 (22,2%) 10 (14,3%) 45 (25,3%) 0.088 
Transthoracic 
echocardiography 
144 (58,1%) 35 (50,0%) 109 (61,2%) 0.141 
Chest radiograph 154 (62,1%) 41 (58,6%) 113 (63,5%) 0.567 
Abdominal ultrasound 42 (16,9%) 9 (12,8%) 33 (18,5%) 0.376 
Magnetic resonance imaging 10 (4,0%) 5 (7,1%) 5 (2,8%) 0.229 
Angiography 25 (10,1%) 7 (10,0%) 18 (10,1%) 0.835 
ACS-like electrocardiogram 68 (27,4%) 29 (41,4%) 39 (21,9%) 0.003 
Treatment 
Surgical/endovascular 
treatment 
173 (69,7%) 48 (68,6%) 125 (70,2%) 0.919 
Only medical treatment 75 (30,2%) 22 (31,4%) 53 (29,8%) 0.919 
Outcome 
In-hospital death 55 (22,2%) 20 (28,6%) 35 (19,7%) 0.177 
In-h death in patients 
surgically treated  
31/173 (17,9%) 9/48 (18,7%) 22/125 (17,6%) 0.964 
In-h death in patients treated 
with medical therapy 
24/75 (32,0%) 11/22 (50,0%) 13/53 (24,5%)  0.060 
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Delays (median, Q1-Q3) 
Pre-hospital delay, min                  90 (50-190) 95 (49-227) 87 (50-183) 0.21 
In-hospital delay, min              190 (101-406) 210 (103-829) 177 (100-342) 0.042 
Global delay, min  347 (195-895) 439 (197-1500) 313 (195-725) 0.035 
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Table 4. Univariate and multivariate analysis for late in-hospital diagnosis (cutoff > 75 th percentile).   
 
Tn indicates Troponin; ACS, acute coronary syndromes; and SBP, systolic blood pressure.   
 
 
 
 
 
Variable Univariate analysis Multivariate analysis 
 OR (95% CI) P OR (95% CI) P 
Dyspnea  2.65 (1.48 - 4.74) .001 2.43 (1.29-4.59) .006 
Pleural effusion 2.01 (1.28 - 3.43) .003 2.02 (1.16-3.50) .01 
Troponin positivity (vs.  neg 
Tn +Tn unavailable) 
1.87 (1.07-3.26) .026 1.92 (1.05-3.52) .03 
Pericardial effusion 1.72 (1.07-2.77) .02   
Transfer from primary hospital 1.55 (0.89-2.72) .12   
Syncope 1.46 (0.77-2.79) .24   
Aortic regurgitation 1.27 (0.81 -2.01) .29   
Hypertension (history of) 1.20 (0.69-2.08) .50   
ACS-like ECG 1.15 (0.69-1.93) .57   
Age (for each 1 year increase) 0.99 (0.98 - 1.01) .74   
Cardiac tamponade 0.91 (0.42-2.03) .82   
Male gender  0.75 (0.46-1.20) .24   
Pulse deficit 0.51 (0.28-0.95) .03   
SBP < 90 mmHg 0.51 (0.25-1.01) .06 0.31 (0.14-0.68) .003 
Back pain 0.48 (0.31-0.77) .002 0.51 (0.31-0.86) .01 
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Table 5. Univariate and multivariate analysis for composite endpoint (in-hospital delay, coronary 
angiography, antithrombotic therapy). 
 
Tn indicates Troponin; ACS, acute coronary syndromes; and SBP, systolic blood pressure.   
 
 
 
 
 
Variable Univariate analysis Multivariate analysis 
 OR (95% CI) P OR (95% CI) P 
Dyspnea  2.17 (1.23-3.84) 0.008 2.30 (1.21-4.37) 0.01 
Syncope 1.68 (0.91-3.11) 0.09 2.13 (1.07-4.48) 0.03 
ACS-like ECG 1.87 (1.16-3.01) 0.01 2.12 (1.26-3.59) 0.005 
Pleural effusion 2.04 (1.27-3.28) 0.003 1.8 (1.06-3.06) 0.029 
Pericardial effusion 1.6 (1.01-2.51) 0.044   
Troponin positivity                 
(vs.  neg Tn +Tn unavailable) 
1.64 (0.95-2.8) 0.073   
Aortic regurgitation 1.48 (0.96 -2.29) 0.07   
Transfer from primary hospital 1.17 (0.67-2.03) 0.58   
Hypertension (history of) 1.12(0.67-1.87) 0.67   
Age (for each 1 year increase) 0.99 (0.98 - 1.01) 0.66   
Cardiac tamponade 0.83 (0.39-1.77) 0.63   
Male gender  0.86 (0.55-1.35) 0.50   
Back pain 0.57 (0.37-0.88)  0.01 0.61 (0.37-0.99) 0.047 
Pulse deficit 0.57 (0.32-0.99) 0.05 0.50 (0.27-0.93) 0.029 
SBP < 90 mmHg 0.61 (0.33-1.13) 0.12 0.34 (0.16-0.72) 0.004 
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Table 6. Univariate and multivariate analysis for in-hospital mortality.  
 
 
Tn indicates Troponin; ACS, acute coronary syndromes; and SBP, systolic blood pressure.   
 
 
 
 
 
Variable Univariate analysis Multivariate analysis 
 OR (95% CI) P OR (95% CI) P 
Pleural effusion 3.16 (1.66-5.99) 0.001      2.28 (1.17-4.57)  0.02    
Dyspnea 2.31 (1.29-7.2) 0.001 2.92 (1.30-6.54) 0.009 
Shock 2.17 (1.02-4.63) 0.043      2.21(0.99-4.96) 0.056      
Stanford type A 1.56 (1.03 - 4.34) 0.140 2.05 (0.96 - 4.38) 0.063 
ACS-like ECG 1.93 (1.01-3.59) 0.047        
Cardiac tamponade 1.92 (0.84- 4.39) 0.121         
Troponin positivity 1.63 (0.86-3.10) 0.131        
Diagnostic delay > 75 th 
percentile 
1.31 (0.67-256) 
 
0.43        
SBP < 90 mmHg 1.27 (0.59-2.74) 
 
0.53   
Syncope 1.15 (0.50-2.59) 0.74        
Age (for each 1 year 
increase) 
1.06 (1.03-1.09 0.001 1.05 (1.02-1.09)  0.001 
Male gender  0.67 (0.36-1.25) 0.22   
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Table 7. Univariate and multivariate analysis for in-hospital mortality of surgically treated Stanford 
type A patients. 
 
 
ACS indicates acute coronary syndromes.  
 
 
 
 
 
 
 
 
 
Variable Univariate analysis Multivariate analysis 
 OR (95% CI) P OR (95% CI) P 
ACS-like ECG 2.24 (1.11-4.49) 0.02 2.26 (1.10-4.60) 0,025 
Pleural effusion 2.14 (1.03-4.59) 0,049 1.89 (0.80-4.24) 0,123 
Shock 2.24 (1.04-4.81) 0,038   
Cardiac tamponade 1.82 (0.71-4.31) 0.168   
Troponin positivity 1.02 (0.39-2.70) 0.131   
Age (for each 1 year 
increase) 
1.03 (1.01-1.07) 0,012 1.04 (1.01-1.07) 0,015 
Surgical delay (for each 
minute increase) 
0.99 (0.99-1.01) 0,74   
Male gender  0.93 (0.41-1.82) 0,846   
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Supplementary Table 1 A. Risk factors and clinical characteristics in overall study population 
according to Troponin T results availability. 
 
VARIABLE 
 
OVERALL 
(n=398) 
 
Troponin T  
available 
(n=248) 
 
Troponin T       
unavailable 
(n=150) 
 
P  
value 
Patients’ characteristics 
Age (yrs), mean ± SD 66,7 ± 13 68 ± 13 65 ± 14 0,031 
Stanford A 258 (64,8%) 167 (67,3%) 91 (60,7%) 0,214 
Men 266 (66,8%) 166 (66,9%)  100 (66,7%) 0,956 
Hypertension (history) 304 (76,4%) 191 (77%) 113 (75,3%) 0,794 
Anti-hypertensive therapy 263 (66,1%) 166 (66,9%) 97 (64,7%) 0,723 
Marfan syndrome 7 (2,1%) 3 (1,2%) 4 (2,7%) 0,498 
Bicuspid aortic valve  9 (2,3%) 7 (2,8%) 2 (1,3%) 0,535 
Aortic coarctation 1 (0,3%) 1 (0,4%) 0 (0%) 0,799 
Known thoracic aortic aneurysm 20 (5%) 17 (6,8%) 3 (2%) 0,056 
Re-dissection 6 (1,5%) 1 (0,4%) 5 (3,3%) 0,057 
Previous stroke 22 (5,5%) 15 (6%) 7 (4,7%) 0,72 
Coronary artery disease (history) 28 (7%) 19 (7,7%) 9 (6%) 0,67 
Clinical features at presentation 
Systolic blood pressure (mm Hg) 145 ± 42  
(389/398) 
146 ± 42 
(244/248) 
145 ± 41 
(145/150)  
0,816 
Systolic blood pressure ≤ 90 mm Hg 68/389 (17,5%) 43/244 (17,6%) 25/145 
(17,2%) 
0,915 
Systolic blood pressure > 160 mm Hg 125/389 
(32,1%) 
82/244 (33,6%) 43/145 
(29,7%) 
0,487 
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Back pain 194 (48,7%) 116 (46,8%) 78 (52%) 0,364 
Chest pain  261 (65,6%) 186 (75%) 75 (50%) <0,001 
Migratory pain  51 (12,8%) 32 (12,9%) 19 (12,7%) 0,931 
Abdominal pain 110 (27,6%) 72 (29%) 38 (25,3%) 0,494 
Pain plus syncope 34 (8,5%) 27 (10,9%) 7 (4,7%) 0,049 
Pain plus shock 44 (11,1%) 28 (11,3%) 16 (10,7%) 0,978 
Pain plus cerebrovascular accident 12 (3%) 9 (3,6%) 3 (2%) 0,536 
Pain plus paraplegia 10 (2,5%) 4 (1,6%) 6 (4%) 0,253 
Peripheral pulse deficits 91 (22,8%) 54 (21,8%) 37 (24,7%) 0,587 
Dyspnea 58 (14,6%) 36 (14,5%) 22 (14,7%) 0,916 
Autonomic symptoms 155 (38,9%) 105 (42,3%) 50 (33,3%) 0,093 
Shock within 12 of admission 57 (14,3%) 37 (14,9%) 20 (13,3%) 0,772 
ACS-like ECG + chest pain 72 (18,1%) 51 (20,6%) 21 (14%) 0,13 
Disease complications 
Cardiac tamponade 38 (9,5%) 30 (12,1%) 8 (5,3%) 0,04 
Pleural effusion 99 (24,9%) 62 (25%) 37 (24,7%) 0,964 
Pericardial effusion 123 (30,9%) 88 (35,5%) 35 (23,3%) 0,015 
Periaortic effusion 63 (15,8%) 41 (16,5%) 22 (14,7%) 0,725 
Moderate/severe aortic regurgitation 106 (26,6%) 70 (28,2%) 36 (24%) 0,42 
Coronary ostia involvment 22 (5,5%) 13 (5,2%) 9 (6%) 0,925 
Presence of intramural hematoma 117 (29,4%) 76 (30,6%) 41 (27,3%) 0,556 
Presence of plaque rupture/ulceration 25 (6,3%) 18 (7,3%) 7 (4,7%) 0,413 
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Supplementary Table 1B.  Instrumental examinations, treatment and outcome in overall study 
population and according to Troponin T availability. 
 
VARIABLE 
 
OVERALL 
(n=398) 
 
Troponin T  
available 
(n=248) 
 
Troponin T       
unavailable 
 (n=150) 
 
P  
value 
Instrumental examinations 
Computed tomography 372 (93,5%) 232 (93,5%) 140 (93,3%) 0,9 
Transesophageal echocardiography 87 (21,8%) 55 (22,2%) 32 (21,3%) 0,942 
Transthoracic echocardiography 222 (55,8%) 144 (58,1%) 78 (52%) 0,282 
Chest radiograph 237 (59,5%) 154 (62,1%) 83 (55,3%) 0,22 
Abdominal ultrasound 78 (19,6%) 42 (16,9%) 36 (24%) 0,112 
Magnetic resonance imaging 20 (5%) 10 (4%) 10 (6,7%) 0,353 
Angiography 42 (10,6%) 25 (10,1%) 17 (11,3%) 0,821 
ACS-like electrocardiogram 102 (25,6%) 68 (27,4%) 34 (22,7%) 0,35 
Treatment 
Surgery/Endovascular  287 (72,1%) 173 (69,7%) 114 (76%) 0,219 
Only medical treatment 111 (27,9%) 75 (30,2%) 36 (24%) 0,219 
Outcome 
In-hospital death 87 (21,8%) 55 (22,2%) 32 (21,3%) 0,942 
In-h death of patients surgically treated  55/287 (19,2%) 31/173 (17,9%) 24/114 
(21,1%) 
0,612 
In-h death of patients treated with 
medical therapy 
32/111 (8%) 24/75(32,1%) 8/36 (22,2%) 0,400 
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Supplementary Table 2.A Baseline clinical characteristics according to Stanford type in patients 
with available troponin values.  
 
VARIABLE 
 
OVERALL 
(n=248) 
 
Type A 
(n=167) 
 
Type B 
(n=81) 
 
P  
value 
Patients’ characteristics 
Age (yrs), mean ± SD 68 ± 13 68 ± 13 67 ± 13 0,57 
Men 166 (66,9%) 105 (62,9%) 61 (75,3%) 0,071 
Hypertension (history) 191 (77%) 127 (76%) 64 (79%) 0,719 
Anti-hypertensive therapy 166 (66,9%) 117 (70,1%) 49 (60,5%) 0,175 
Marfan syndrome 3 (1,2%) 1 (0,6%) 2 (2,5%) 0,519 
Bicuspid aortic valve  7 (2,8%) 5 (3%) 2 (2,5%)  0,861 
Aortic coarctation 1 (0,4%) 0 (0%) 1 (1,2%) 0,711 
Known thoracic aortic aneurysm 17 (6,8%) 11 (6,6%) 6 (7,4%) 0,978 
Re-dissection 1 (0,4%) 1 (0,6%) 0 (0%) 0,711 
Previous stroke 15 (6%) 10 (6%) 5 (6,2%) 0,821 
Coronary artery disease (history) 19 (7,7%) 13 (7,8%) 6 (7,4%) 0,881 
Clinical features at presentation 
Systolic blood pressure (mm Hg) 146 ± 42 
(244/248) 
134 ± 38 
(163/167) 
170 ± 40 
(81/81)  
<0,001 
Systolic blood pressure ≤ 90 mm Hg 43/244 (17,6%) 36/163 (22,1%) 7/81  
(8,6%) 
0,016 
Systolic blood pressure > 160 mm Hg 82/244 (33,6%) 37/163 (22,7%) 45/81 (55,6%) <0,001 
Back pain 116 (46,8%) 59 (35,3%) 57 (70,4%) <0,001 
Chest pain  186 (75%) 128 (76,6%) 58 (71,6%) 0,482 
Migratory pain  32 (12,9%) 23 (13,8%) 9 (11,1%) 0,701 
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Abdominal pain 72 (29%) 34 (20,4%) 38 (46,9%) <0,001 
Pain plus syncope 27 (10,9%) 23 (13,8%) 4 (4,9%) 0,06 
Pain plus shock 28 (11,3%) 26 (15,6%) 2 (2,5%) 0,004 
Pain plus cerebrovascular accident 9 (3,6%) 8 (4,8%) 1 (1,2%) 0,297 
Pain plus paraplegia 4 (1,6%) 3 (1,8%) 1 (1,2%) 0,835 
Peripheral pulse deficits 54 (21,8%) 34 (20,4%) 20 (24,7%) 0,541 
Dyspnea 36 (14,5%) 22 (13,2%) 14 (17,3%) 0,503 
Autonomic symptoms 105 (42,3%) 80 (47,9%) 25 (30,9%) 0,016 
Shock within 12 of admission 37 (14,9%) 34 (20,4%) 3 (3,7%) 0,001 
ACS-like ECG + chest pain 51 (20,6%) 43 (25,7%) 8 (9,9%) 0,006 
Disease complications 
Cardiac tamponade 30 (12,1%) 30 (18%) 0 (0%) <0,001 
Pleural effusion 62 (25%) 41 (24,6%) 21 (25,9%) 0,938 
Pericardial effusion 88 (35,5%) 79 (47,3%) 9 (11,1%) <0,001 
Periaortic effusion 41 (16,5%) 24 (14,4%) 17 (21%) 0,257 
Moderate/severe aortic regurgitation 70 (28,2%) 58 (34,7%) 12 (14,8%) 0,002 
Coronary ostia involvement 13 (5,2%) 13 (7,8%) 0 (0%) 0,023 
Presence of intramural hematoma 76 (30,6%) 46 (27,5%) 30 (37%) 0,17 
Presence of plaque rupture/ulceration 18 (7,3%) 5 (3%) 13 (16%) <0,001 
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Supplementary Table 2.B Instrumental examinations, treatment and outcome according to Stanford 
type in patients with available troponin values. 
 
VARIABLE 
 
OVERALL 
(n=248) 
 
Type A 
(n=167) 
 
Type B 
(n=81) 
 
P  
value 
Instrumental examinations 
Computed tomography 232 (93,5%) 153 (91,6%) 79 (97,5%) 0,133 
Transesophageal echocardiography 55 (22,2%) 44 (26,8%) 11 (13,6%) 0,035 
Transthoracic echocardiography 144 (58,1%) 99 (59,3%) 45 (55,6%) 0,674 
Chest radiograph 154 (62,1%) 96 (57,5%) 58 (71,6%) 0,044 
Abdominal ultrasound 42 (16,9%) 24 (14,4%) 18 (22,2%) 0,172 
Magnetic resonance imaging 10 (4%) 4 (2,4%) 6 (7,4%) 0,124 
Angiography 25 (10,1%) 13 (7,8%) 12 (14,8%) 0,134 
ACS-like electrocardiogram 68 (27,4%) 52 (31,1%) 16 (19,8%) 0,083 
Troponin positivity 70 (28,2%) 50 (29,9%) 20 (24,7%) 0,470 
Treatment 
Surgery/Endovascular  173 (69,7%) 138 (82,6%) 35 (43,2%) <0,001 
Only medical treatment 75 (30,2%) 29 (17,4%) 46 (56,8%) 
Outcome 
In-hospital death 55 (22,2%) 42 (25,1%) 13 (16%) 0,146 
In-h death of patients surgically treated  31/173  
(17,9%) 
25/138  
(18,1%) 
6/35  
(17,1%) 
0,91 
In-h death of patients treated with 
medical therapy 
24/75 
 (32%) 
17/29  
(58,6%) 
7/46  
(15,2%) 
<0,001 
Delays (median, Q1-Q3) 
Pre-hospital delay, min 90 (50-190) 75 (45-180) 120 (60-233) 0,08 
In-hospital delay, min 190 (101-406) 180 (113-536) 170 (95-277) 0,57 
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Global delay, min 347 (195-895) 255 (158-716) 290 (155-510) 0,12 
Surgical delay, min NA 180 (162-306) NA NA 
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Supplementary Table 3. Clinical profile and diagnostic delays according to ECG/TnT findings. 
 ACS-like 
ECG +/ 
Tn+ 
      n = 29 
ACS-like 
ECG - / 
Tn+ 
 
n = 41 
ACS-like 
ECG +/ 
Tn- 
 
   n = 39 
ACS-like 
ECG - / 
Tn- 
 
   n = 139 
 
       P 
P p P value 
Characteristics  
 
 
 
      
Age, mean (SD), y 69 ± 15 69 ± 13 67 ± 12 67 ± 12 .24 f  0.125 
Male gender,  No. (%) 17 (58%)  23 (56%) 27 (69%) 99 (71%) .305   0.975 
Type of dissection      .377           0.089 
   Stanford type A 23 (79%) 27 (66%) 29 (74%) 88 (63%)     
   Stanford type B 6 (21%) 14 (34%) 10 (26%) 51 (37%)     
Hypertension , No. (%) 19 (66%) 32 (78%) 32 (82%) 96 (69%) .365   0.055 
History of CAD 2 (7%)  5 (12%) 2 (5%) 8 (6%) .706   0.043 
Symptoms         
   Chest pain 21 (72%) 25 (61%) 30 (77%) 97 (70%) .637   0.267 
   Back pain 14 (48%) 18 (44%) 15 (38%) 69 (50%) .871   0.114 
   Syncope 8 (28%) 7 (17%) 5 (13%) 17(12%) .256   0.055 
   Dyspnea 9 (31%)  4 (8%) 4 (10%) 19 (14%) .06   0.021 
   Autonomic symptoms 13 (45%) 14 (34%) 15 (38%) 63 (45%) .513   0.006 
Signs         
   SBP < 90 mm  Hg 9 (31%) 8 (20%) 8 (21%) 18 (13%) .142   <0.001 
   SBP >160 mm Hg 9 (31%) 14 (34%) 15 (38%) 44 (32 %) .615   0.268 
Pulse deficit 8 (28%) 9 (22%) 10 (26%) 27(19%) .973   0.867 
Pleural effusion 8 (28%)  13 (32%) 13 (33%) 28 (20%) .754   0.015 
Cardiac tamponade 1 (3%) 7 (17%) 6 (15%) 16 (11%) .445   0.044 
Moderate/severe aortic 
regurgitation 
14 (48%) 4 (10%) 15 (38%) 28(20%) .001   0.021 
Coronary osthia involvement 4 (14%)  1 (2%) 4 (10%) 4 (3%) .05   <0.001 
Shock 9 (31%) 6 (15%) 6 (15%) 16 (11%) .08   <0.001 
Surgery 20 (69%) 28 (68%) 27 (69%) 98 (70%) .99    
In-hospital mortality 10 (34%) 10 (24%) 11 (28%) 24 (17%) .190   0.002 
Delays (median, Q1-Q3)         
Pre-hospital delay, min  100 (47-297) 90 (50-175) 80 (47-184) 88 (50-180) .65    
In-hospital delay, min  
 
300 (260-
1500) 
180 (100-
580) 
180 (122-
285) 
170 (93-341) .01    
Global delay, min   
 
810 (260-
1500) 
330 (191-
1091) 
280 (198-
707) 
330 (195-
746) 
.002    
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Supplementary Table 4. Instrumental findings, antithrombotic medications, and interventions of 
positive troponin patients with AAS presenting as “true” ST-elevation myocardial infarction. 
Patients Stanford 
type A 
ECG leads (ST-
segment 
elevation) 
Shock Coronary 
angiography 
PCI  Antiplatele
ts drugs 
Anticoagulant 
1 Yes D2,D3,aVF and 
V1-V2 (right 
ventricle) 
Yes  No No Yes          
(aspirin) 
No 
2 Yes V2-V5 Yes No No Yes            
(aspirin) 
Yes              
(heparin) 
3 Yes D2,D3,aVF No Yes Yes Yes             
(aspirin, 
clopidogrel, 
abciximab) 
Yes              
(heparin) 
4 No D2,D3,aVF No No No No No 
5 No D2,D3,aVF 
(prior MI)  
No No No Yes             
(aspirin) 
No 
6 Yes D2,D3,aVF No No No No No 
7 Yes D2,D3,aVF and 
V1-V2 (right 
ventricle) 
Yes Yes No Yes       
(aspirin, 
clopidogrel
) 
Yes         
(heparin) 
8 Yes D2,D3,aVF No No No No No 
9 Yes V3-V6 No Yes No Yes 
(aspirin) 
Yes (heparin) 
Total 77%                   
(7/9) 
77%                 
inferior leads 
33% 
(3/9) 
33%                     
(3/9) 
11% 
(1/9) 
66%        
(6/9) 
44%                      
(4/9) 
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(7/9)  
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Supplementary Table 5A. Baseline clinical characteristics in patients alive or dead at hospital 
discharge.  
 
VARIABLE 
 
OVERALL 
(n=398) 
 
Alive at hospital 
discharge 
 (n=310) 
 
Dead at hospital 
discharge 
 (n=88) 
 
P  
Value 
Type A 258 (64,8%) 190 (61,3%) 68 (77,3%) 0,008 
Type B 140 (35,2%) 120 (38,7%) 20 (22,7%) 
Patients’ characteristics 
Age (yrs), mean ± SD 66,7 ± 13,3 65,2 ± 13,4 71,6 ± 5,5 <0,001 
Men 266 (66,8%) 214 (69%) 52 (59,1%) 0,105 
Hypertension (history) 304 (76,4%) 237 (76,5%) 67 (76,1%) 0,936 
Anti-hypertensive therapy 263 (66,1%) 205 (66,1%) 58 (65,9%) 0,929 
Marfan syndrome 7 (2,1%) 6 (1,9%) 1 (1,1%) 0,965 
Bicuspid aortic valve  9 (2,3%) 8 (2,6%) 1 (1,1%)  0,691 
Aortic coarctation 1 (0,3%) 1 (0,3%) 0 (0%) 0,501 
Known thoracic aortic 
aneurysm 
20 (5,0%) 13 (4,2%) 7 (8%) 0,263 
Re-dissection 6 (1,5%) 5 (1,6%) 1 (1,1%) 0,864 
Clinical features at presentation 
Systolic blood pressure 
(mm Hg) 
145 ± 42  
(389/398) 
147 ± 21 
(303/310) 
140 ± 7 
(86/88) 
0,003 
Systolic blood pressure ≤ 
90 mm Hg 
68/389 
(17,5%) 
46/303 (15,2%) 22/86 (25,6%) 0,037 
Systolic blood pressure > 
160 mm Hg 
125/389 
(32,1%) 
99/303 (32,8%) 26/86 (29,9%) 0,767 
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Back pain 194 (48,7%) 157 (50,6%) 37 (42%) 0,192 
Chest pain  261 (65,6%) 205 (66,1%) 56 (63,6%) 0,759 
Migratory pain  51 (12,8%) 39 (12,6%) 12 (13,6%) 0,936 
Abdominal pain 110 (27,6%) 84 (27,1%) 26 (29,5%) 0,750 
Pain plus syncope 34 (8,5%) 23 (7,4%) 11 (12,5%) 0,197 
 
Pain plus shock 44 (11,1%) 24 (7,7%) 20 (22,7%) <0,001 
Pain plus cerebrovascular 
accident 
12 (3,0%) 9 (2,9%) 3 (3,4%) 0,914 
Pain plus paraplegia 10 (2,5%) 6 (1,9%) 4 (4,5%) 0,320 
Peripheral pulse deficits 91 (22,8%) 66 (21,3%) 25 (28,4%) 0,208 
Dyspnea 58 (14,6%) 37 (11,9%) 21 (23,9%) <0,001 
Autonomic symptoms 155 (38,9%) 113 (36,5%) 42 (47,7%) 0,073 
Shock within 12 of 
admission 
57 (14,3%) 34 (11%) 23 (26,1%) <0,001 
ACS-like ECG + chest 
pain 
72 (18,1%) 48 (15,5%) 24 (27,3%) 0,017 
Disease complications 
Cardiac tamponade 38 (9,5%) 24 (7,7%) 14 (15,9%) 0,036 
Pleural effusion 99 (24,9%) 66 (21,3%) 33 (37,5%) 0,003 
Pericardial effusion 123 (30,9%) 87 (28,1%) 36 (40,9%) 0,030 
Periaortic effusion 63 (15,8%) 45 (14,5%) 18 (20,5%) 0,237 
Moderate/severe aortic 
regurgitation 
106 (26,6%) 68 (21,9%) 38 (43,2%) <0,001 
Coronary ostia 
involvement 
22 (5,5%) 10 (3,2%) 12 (13,6%) <0,001 
Presence of intramural 117 (29,4%) 96 (31%) 21 (23,9%) 0,247 
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hematoma 
Presence of plaque 
rupture/ulceration 
25 (6,3%) 14 (4,5%) 11 (12,5%) 0,013 
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Supplementary Table 5B. Instrumental examinations and treatment in patients alive or dead at 
hospital discharge.  
 
VARIABLE 
 
OVERALL 
 
(n=398) 
 
Alive at 
hospital 
discharge 
(n=310) 
 
Dead at 
hospital 
discharge 
(n=88) 
 
P  
value 
Instrumental examinations 
Computed tomography 372 (93,5%) 293 (94,5%) 79 (89,8%) 0,179 
Transesophageal echocardiography 87 (21,8%) 60 (19,4%) 27 (30,7%) 0,034 
Transthoracic echocardiography 222 (55,8%) 174 (56,1%) 48 (54,5%) 0,887 
Chest radiograph 237 (59,5%) 185 (59,7%) 52 (59,1%) 0,981 
Abdominal ultrasound 78 (19,6%) 68 (21,9%) 10 (11,4%) 0,040 
Magnetic resonance imaging 20 (5,0%) 16 (5,2%) 4 (4,5%) 0,966 
Angiography 42 (10,6%) 32 (10,3%) 10 (11,4%) 0,933 
ACS-like electrocardiogram 102 (25,6%) 69 (22,3%) 33 (37,5%) 0,006 
Troponin positivity 70/248 (28,2%) 50/192 (26%) 20/56 (35,7%) 0,213 
Treatment 
Surgery/Endovascular  287 (72,1%) 232 (74,8%) 55 (62,5%) 0,032 
 Only medical treatment 111 (27,9%) 78 (25,2%) 33 (37,5%) 
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Figure 1. Impact of Troponin elevation and ACS-like ECG abnormalities on in-hospital diagnostic 
time and inappropriate treatments. 
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Figure 2. Pathophysiological mechanisms underlying troponin positivity in acute aortic 
syndromes. 
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PART II  
ACUTE HEART FAILURE IN PATIENTS WITH ACUTE AORTIC 
SYNDROME: PATHOPHYSIOLOGY AND CLINICAL-PROGNOSTIC 
IMPLICATIONS. 
 
Background 
Acute heart failure (AHF) is rightly regarded as not a single disease but a syndrome that can 
be caused by different mechanisms and different diseases. Although it is known that aortic 
dissection is one of the possible causes of AHF (29,30), the literature is mainly represented 
by case reports (31-36). The only systematic approach to this issue dates back to 10 years ago 
(30). A research letter of 2005 summarizes findings from  IRAD registry but only partially 
specifies the mechanisms leading to AHF.  Since then, diagnostic tools and surgical 
techniques have developed enough to warrant a revision of this serious complication of AAS 
in the current "era" 
 
Aims 
The objectives of this study were to assess the frequency of acute heart failure (AHF) in 
AAS, to characterize the clinical and instrumental profile of these patients, to explore 
pathophysiological mechanisms underlying this condition and to evaluate the impact on 
treatment and in-hospital mortality.  
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Methods 
Setting, patients, and data collection 
AESA (Archivio Elettronico Sindromi Aortiche acute) registry includes data from all 
consecutive patients referred to our Institution between 2000 and 2013 who received a final 
diagnosis of spontaneous Acute Aortic Syndrome. The S.Orsola - Malpighi University 
Hospital is the referral centre for AAS treatment in a metropolitan hospital network that 
covers Bologna and its hinterland (catchment area approximately 1.000.000 people).  
The database contains information on patient demographics, history, clinical presentations, 
physical findings, laboratory findings, imaging study results, details of medical and surgical 
treatment, and patient outcomes, including mortality. Baseline characteristics included 
“classic” risk factors for AAS and cardiovascular/ non-cardiovascular comorbidities. Pain 
features and presentation symptoms  were reported in detail. Two experienced cardiologists 
blindly reviewed all the electrocardiograms. Laboratory findings included information on 
cardiac troponin test, when performed according to the standard protocol used in chest pain 
unit (until 2010 the standard test was used, then replaced by high sensitivity assay).  Imaging 
was interpreted by specialized radiologists and echocardiographers and entered into the data 
form. Helical computed tomography, transesophageal/transthoracic echocardiography, 
magnetic resonance imaging, and/or angiography were obtained and reviewed.  
Details of the relevant diagnostic time intervals were prospectively collected: 1) symptoms 
onset to presentation at any hospital; 2) hospital presentation to final AAS diagnosis; 3) 
global diagnostic delay (symptoms onset to final AAS diagnosis at any hospital).  
Surgical delay (for Stanford type A) was defined by the time gap between symptom onset and 
operating room.  
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Patients with symptoms onset >14 days at hospital presentation were not included in the 
registry. AAS (aortic dissection, penetrating ulcer and intramural hematoma) were defined 
according to the Stanford classification.  
In all cases (presenting at either a hub or a spoke centre) the diagnosis was confirmed by a 
multidisciplinary team that included a cardiologist, heart surgeon and cardiovascular 
radiologist.  
The study was approved by the local ethics committee and all patients provided written 
informed consent.  
 
Definitions and mechanisms 
Patients with AHF were identified by the presence of  dyspnea as presentation symptom or 
radiological signs of pulmonary congestion or cardiogenic shock, including patients with 
cardiac tamponade. Shock was defined as sustained hypotension (systolic blood pressure <90 
mm Hg for >30 minutes) accompanied by clinical signs of peripheral/cerebral hypoperfusion 
(24).  We used standard definition for cardiac tamponade (25).  
Clinical and instrumental  data of each patients with AHF were systematically reviewed in 
order to identify the mechanisms leading to AHF.  A distinction between “main” and 
“contributing” mechanism was made by two cardiologists on a case-by-case basis by using  
the following hierarchy: cardiac tamponade, severe aortic regurgitation, myocardial ischemia, 
ischemia, hypertensive crisis.  
Electrocardiogram (ECG) was considered to be acute coronary syndrome (ACS)-like in the 
presence of ≥ 1 of the following characteristics: 1) ST-segment elevation in two contiguous 
leads with the cut-point ≥ 0.1 mV in all leads other than leads V2-V3, where the cut- point is 
≥ 0.2 mV; 2) horizontal or down-sloping ST-segment depression ≥ 0.05 mV in two 
contiguous leads; 3) T-wave inversion ≥ 0.1 mV in two contiguous leads. 
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The diagnosis of troponin positivity using standard cTnT testing was made in the presence of 
at least one value of cTnT > 30 ng/L (10% CV cut-off). When HS-cTnT was used, the 
diagnosis of troponin positivity was made in the presence of at least one value of HS-cTnT > 
14 ng/L (URL).  
Myocardial ischemia was defined by the presence of ACS-like ECG findings and/or troponin 
positivity.   
Aortic regurgitation  was considered a possible mechanism of AHF only  when severe or 
moderate-to-severe at transthoracic/transesophageal echocardiography.  Mechanisms leading 
to aortic regurgitation in type A AAS were classified according to previous study by 
Movsowitz  et Al. (37).  
Hypertensive crisis was defined according to current ESC guidelines on arterial hypertension 
(systolic blood pressure > 180 mmHg or diastolic blood pressure > 110 mmHg) (38).   
Pleural effusion was diagnosed by chest x-ray or CT scan. Pericardial effusion was diagnosed 
by transthoracic/transesophageal echocardiogram, cardiac tomogram, or magnetic resonance 
imaging. Periaortic hematoma was diagnosed by transthoracic/ transesophageal 
echocardiogram, CT, or magnetic resonance imaging (26). 
 
Statistical analysis  
Categorical data were expressed as proportions and continuous variables reported as 
e range (IQR), as appropriate. The Chi-square test for 
categorical variables was used to compare groups. The two-tailed Student t test was used to 
compare normally distributed continuous variables.  Comparison of non-normally distributed 
variables were conducted using the Mann-Whitney U test.  
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We explored the association between diagnostic delay and clinical-instrumental profile of the 
patient. In order to identify unusually long diagnostic times we used 75
th
 percentile of in-
hospital delay as cut-off in keeping with previous analyses (15).  
Logistic regression analysis was performed to identify predictors of in-hospital delay and of 
in-hospital mortality. Non correlated variables with p<0.2 at the univariate analyses were 
included in the multivariate analysis. Model discrimination was assessed with the c-statistic, 
and model calibration was assessed with the Hosmer-Lemeshow statistic.  
A p value < 0.05 in the two-tailed tests was considered significant. All analyses were 
performed with the STATA/SE 12.1 software for Windows (StataCorp LP, College Station, 
Texas, USA). 
 
Results 
Frequency and profile of patients presenting with AHF  
During the study period a total of 398 patients received a final diagnosis of spontaneous AAS 
and were entered into the AESA Registry.  
Epidemiological, clinical, instrumental and outcome findings of the patients presenting with / 
without AHF are shown in Tables 1A and 1B.  The overall frequency of AHF among patients 
with AAS was  28% (113/398); presentation with AHF was more common in patients with 
Stanford type A AAS (84/258, 32%) vs. Stanford type  B (29/140, 20%), (p = 0.01). 
Regarding clinical history, prior coronary artery disease (CAD) was the only feature more 
often observed among patients presenting with AHF. These patients were more likely to 
present significant aortic regurgitation, pleural effusion and ACS-like ECG findings. On the 
other hand, patients without AHF had a higher systolic blood pressure and more frequently 
reported back or abdominal pain.  
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Pathophysiological Mechanism 
A characterization of  probable mechamism(s) underlying AHF was possible only  in 89 of 
113 patients.  In Type A patients aortic insufficiency was the single most frequent mechanism 
(alone or in combination) followed by cardiac tamponade, whereas  myocardial ischemia and 
hypertensive crisis were the leading causes of AHF in Type B (Table 2). Among the 38 
patients with aortic insufficiency,  a spectrum of causes of regurgitation was identified 
including : pre-existing aortic valve disease (bicuspid aortic valve or degenerative leaflet 
thickening); incomplete leaflet closure due to dilatation of the sino-tubular junction,  aortic 
leaflet prolapse/disruption, and prolapse (“intussusception”)  of the dissection flap through 
aortic valve orifice  producing a “funnel effect”.  
 
Diagnostic delays 
Median global diagnostic delay (time to diagnosis) was 307 (Q1-Q3, 180 - 900) minutes. 
Median pre-hospital (time to presentation) and in-hospital delays were 90 (Q1-Q3, 50 - 210) 
minutes and 190 (Q1-Q3, 101-406) minutes respectively (Table 1B). The median time from 
symptom onset to presentation was shorter among patients with AHF whereas no difference 
was noted for both in-hospital and global diagnostic times (Table 1B, Figure 1) . Importantly, 
presentation with AHF wads associated to increased surgical delay among type A AAS 
patients (Figure 2).  
Table 3 shows results of univariate/multivariate analysis of predictors of in-hospital 
diagnostic delay.  Excess risk was related to pleural effusion whereas back pain and pulse 
deficit resulted to be protective from late in-hospital diagnosis. Of note AHF as clinical 
presentation of AAS did not influence in-hospital diagnostic time (OR 1.43 95% CI 0.88-
2.32, p = 0,152).  
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In-hospital outcome 
Overall mortality  of patients presenting with AHF were two-fold compared those presenting 
without (table 4), mainly due to an excess risk in type A pts. Independent predictors of in-
hospital mortality in the whole population and in Type A AAS undergoing surgery are 
reported in table 5 and 7 respectively. AHF was indeed  an independent risk factor in 
conjunction with age, Stanford type A, pleural effusion, ACS-like ECG findings, pulse 
deficit. Surgery or endovascular treatment resulted to be protective.      
 
DISCUSSION  
The main result of our analysis is that AHF  occurs in more than one fourth of patients 
with AAS of both type A and type B, is associated with increased surgical delay and in-
hospital mortality.   
The study population of our single centre series is comparable to that of the largest 
available AAS registry, the IRAD registry, in particular with regard to age (mean value 66.7 
yrs), male prevalence (67%), relative frequency of  Stanford type A, frequency and 
distribution of signs and symptoms at presentation (27). A history of hypertension was the 
most frequent risk factor (76%), while Marfan syndrome and bicuspid aortic valve were 
found only in 2.1% and 2.3% of patients respectively.  
 Presentation with AHF occurred in 28% of our population, ranging from 20% among  
type B patients to 32% of those with type A AAS.  The prevalence reported in IRAD is 
consistently lower (6%), but differences in the definition of AHF can explain this 
discrepancy. While in the study by Januzzi et al (30)  the diagnosis of CHF was based on 
the impressions of the managing physicians as noted in the IRAD case report form, we  
included all the patients with dyspnea at presentation or pulmonary congestion at x-Ray or 
cardiogenic shock  in order to assume as more as possible the unbiased perspective of a 
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physician evaluating an acutely ill patient facing the entire spectrum of diseases underlying 
AHF. Interestingly, in our study both categories of AHF proposed by ESC guidelines (29) are 
represented: 56 of 113 patients presented with pulmonary congestion/oedema  without shock; 
57 of 113 patients presented with hypotension, hypoperfusion or shock.  So the physician 
should consider the possibility of AAS  (when the clinical context is appropriate), in front of 
both presentations of AHF. 
Our registry, although not specifically aimed to investigate the mechanistic aspects,  offers 
several insights into the possible mechanisms underlying AHF during AAS due to the 
prospective collection of many clinical and instrumental variables in all the patients, 
including standard ECG, Troponin values, TTE and TEE.  
It should be noted, first, that the frequency of the possible mechanisms is different between 
type A and type B (Table 2). In type A AAS, aortic regurgitation and cardiac tamponade are 
the main causes of AHF. During AAS cardiac tamponade may cause sudden death but it can 
also occur over a relatively long time leading to progressive heart failure and subsequent 
shock at presentation.  
Aortic regurgitation may be due to a variety of mechanisms which were explored by TE 
echocardiography: 1) incomplete leaflet closure that occurs when the sino-tubular junction 
dilates relative to the aortic annulus resulting in leaflet tethering and a persistent diastolic 
orifice,  2) aortic leaflet prolapse that occurs when the dissection extends into the aortic root 
and disrupts normal leaflet attachment to the aortic wall, thereby resulting in abnormal leaflet 
coaptation and eccentric regurgitation; 3) prolapse of the dissection flap through aortic valve 
orifice 4) pre-existing aortic valve disease (bicuspid aortic valve or degenerative leaflet 
thickening). 
Myocardial ischemia, which leads to left ventricular systolic or diastolic dysfunction,  may be 
related to a clear anatomic obstruction of at least one coronary artery due to coronary 
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dissection or to diastolic apposition of the flap to the ostium. In the remaining cases the 
mechanism, albeit undefined, is probably multifactorial including acute pressure overload in 
patients with or without pre-existing coronary.   
Although most patients with AHF in our series had type A AAS, this study show that as 
many as 25% of patients with AHF had a distal dissection; when AHF is a presenting 
symptom of type B AAS, this may be due to myocardial ischemia  or hypertensive crisis.   
Indeed, 1 out of 3 patients with AHF showed ACS-like ECG abnormalities and/or troponin T 
positivity, irrespective to Stanford subtype.  
The clinical profile of  patients with AHF is similar to that of patients without AHF  
regarding age and risk factors (Table 1A).  On the other hand, AHF patients are more likely 
to have type A AAS, low blood pressure and less likely to present with  back-pain; more 
frequently, however, the pain is associated with syncope and a pleural effusion is detectable 
at chest X-ray.    
Although some of these findings (such as dyspnea and pleural effusion) could theoretically 
lead to long in-hospital delay (15),  median time to diagnosis was not significantly different 
between patients presenting with/without AHF, and AHF was not identified as an 
independent predictor of late in-hospital diagnosis  at multivariable analysis (Table 3). These 
results are consistent with previous findings from IRAD registry (30 ).  
It is possible that the overall perception of increased severity of  AHF patient by the 
physician determined a faster diagnostic work up, and that this fact balanced out an initial 
delay of the hypothesis of AAS; thus, the two effects tended to offset each other.  
Patients with AHF tended to have a shorter median time from symptom onset to presentation 
indeed, probably because of the more severe clinical picture that induces an early access to 
the emergency department.  Conversely, median time to surgical treatment (when performed) 
was  longer among patients presenting with AHF (Figure 2). Notably, in our study as in the 
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IRAD patients with type A AAS and concomitant AHF underwent surgery later than those 
without AHF. Although the exact explanation of this finding is not clear, it could be argued 
that this delay was due to the increased complexity of the management of such patients and to 
the temptation to stabilize them before taking to the operating room. Presentation with AHF 
is an incremental risk factor for  in-hospital mortality of type A AAS patients (both operated 
and not operated) probably due to a more advanced preoperative multi-organ damage. 
 
 
LIMITATIONS 
Our prospective registry refers to a single hub center operating in a rather densely populated 
urban area with a long lasting  hub & spoke organization. So  the findings regarding hospital 
arrival times cannot be generalized to more challenging geographic settings. Inevitably, this 
registry included only patients who reached a final diagnosis of AAS and could not consider 
(or include) the patients that never received a diagnosis of AAS, or had a post-mortem 
diagnosis.  
Our definition of AHF may have overestimated its prevalence in AAS patients. We  included 
indeed all the patients with dyspnea at presentation or pulmonary congestion at x-Ray or 
cardiogenic shock  in order to assume as more as possible the unbiased perspective of a 
physician evaluating an acutely ill patient facing the entire spectrum of diseases underlying 
AHF. Therefore this difference should be taken into account when comparing our study with 
other reports.  
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Table 1A Baseline clinical characteristics in overall study population and according to AHF 
on presentation. 
 
VARIABLE 
 
OVERALL 
(n=398) 
 
AHF   
 (n=113) 
 
No AHF  
(n=285) 
 
P  
value 
Patients’ characteristics 
Age (yrs), mean ± SD 66,7 ± 13,3 69,7 ± 13,4 70,4 ± 13,9 0,647 
Men 266 (66,8%) 69 (61,1%) 197 (69,1%) 0,155 
Hypertension (history) 304 (76,4%) 86 (76,1%) 218 (76,5%) 0,961 
Anti-hypertensive therapy 263 (66,1%) 76 (67,3%) 187 (65,6%) 0,846 
Marfan syndrome 7 (2,1%) 1 (0,9%) 6 (2,1%) 0,68 
Bicuspid aortic valve  9 (2,3%) 3 (2,7%) 6 (2,1%) 0,967 
Aortic coarctation 1 (0,3%) 0 (0%) 1 (0,4%) 0,631 
Known thoracic aortic aneurysm 20 (5,0%) 5 (4,4%) 15 (5,3%) 0,928 
Re-dissection 6 (1,5%) 1 (0,9%) 5 (1,8%) 0,853 
Previous stroke 22 (5,5%) 5 (4,4%) 17 (6%) 0,717 
Coronary artery disease (history) 28 (7,0%) 14 (12,4%) 14 (4,9%) 0,016 
Clinical features at presentation 
Systolic blood pressure (mm Hg) 145 ± 42  
(389/398) 
125 ± 21 
(111/113) 
154 ± 39 
(278/285) 
<0,001 
Systolic blood pressure ≤ 90 mm 
Hg 
68/389  
(17,5%) 
47/111 
(42,3%) 
21/278 
(7,6%) 
<0,001 
Systolic blood pressure > 160 mm 
Hg 
125/389  
(32,1%) 
22/111 
(19,8%) 
103/278 
(37,1%) 
0,002 
Back pain 194 (48,7%) 39 (34,5%) 155 (54,4%) <0,001 
Chest pain  261 (65,6%) 79 (69,9%) 182 (63,9%) 0,304 
Migratory pain  51 (12,8%) 10 (8,8%) 41 (14,4%) 0,186 
Abdominal pain 110 (27,6%) 24 (21,2%) 86 (30,2%) 0,094 
Pain plus syncope 34 (8,5%) 19 (16,8%) 15 (5,3%) <0,001 
Pain plus shock 44 (11,1%) 44 (38,9%) 0 (0%) <0,001 
Pain plus cerebrovascular accident 12 (3,0%) 4 (3,5%) 8 (2,8%) 0,952 
Pain plus paraplegia 10 (2,5%) 2 (1,8%) 8 (2,8%) 0,81 
Peripheral pulse deficits 91 (22,8%) 27 (23,9%) 64 (22,5%) 0,861 
Dyspnea 58 (14,6%) 58 (51,3%) 0 (0%) NA 
Autonomic symptoms 155 (38,9%) 58 (51,3%) 97 (34%) 0,002 
Shock within 12 of admission 57 (14,3%) 57 (50,4%) 0 (0%) NA 
Stanford Type A  258 (64,8%) 84 (74% ) 174 (61,1%)  
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Stanford Type B 140 (35,2%) 29 (25%) 111 (38,9%) 0.017 
Disease complications 
Cardiac tamponade 38 (9,5%) 30 (26,5%) 8 (2,8%) NA 
Pleural effusion 99 (24,9%) 42 (37,2%) 57 (20%) <0,001 
Pericardial effusion 123 (30,9%) 54 (47,8%) 69 (24,2%) <0,001 
Periaortic effusion 63 (15,8%) 23 (20,4%) 40 (14%) 0,160 
Moderate/severe aortic 
regurgitation 
106 (26,6%) 38 (33,6%) 59 (20,7%) 0,05 
Coronary ostia involvement 22 (5,5%) 13 (11,5%) 9 (3,2%) 0,002 
Presence of intramural hematoma 117 (29,4%) 30 (26,5%) 87 (30,5%) 0,507 
Presence of plaque 
rupture/ulceration 
25 (6,3%) 13 (11,5%) 12 (4,2%) 0,013 
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Table 1.B Instrumental examinations, treatment and outcome in overall study population and 
according to AHF at presentation. 
 
VARIABLE 
 
OVERALL 
(n=398) 
 
AHF at 
presentation 
 (n=113) 
 
NO-AHF at 
presentation 
(n=285) 
 
P  
value 
Instrumental examinations 
Computed tomography 372 (93,5%) 99 (87,6%) 273 (95,8%) 0,006 
Transesophageal echocardiography 87 (21,8%) 29 (25,7%) 58 (20,4%) 0,307 
Transthoracic echocardiography 222 (55,8%) 63 (55,8%) 159 (55,8%) 0,916 
Chest radiograph 237 (59,5%) 78 (69%) 159 (55,8%) 0,021 
Abdominal ultrasound 78 (19,6%) 21 (18,6%) 57 (20%) 0,856 
Magnetic resonance imaging 20 (5,0%) 7 (6,2%) 13 (4,6%) 0,676 
Angiography 42 (10,6%) 11 (9,7%) 31 (10,9%) 0,878 
ACS-like electrocardiogram 102 (25,6%) 38 (33,6%) 64 (22,5%) 0,03 
Troponin positivity 70/248  
(28,2%) 
25/69 
(36,2%) 
45/179 
(25,1%) 
0,114 
Treatment 
Surgery/Endovascular  287 (72,1%) 85 (75,2%) 202 (70,9%) 0,455 
Only medical treatment 111 (27,9%) 28 (24,8%) 83 (29,1%) 
Outcome 
In-hospital death 87 (21,8%) 39 (34,5%) 48 (16,8%) <0,001 
In-h death of patients surgically 
treated  
55 (13,8%) 27 (23,9%) 28 (9,8%) <0,001 
In-h death of patients treated with 
medical therapy 
32 (8,0%) 12 (10,6%) 20 (7%) 0,324 
Delays (median, Q1-Q3) 
Pre-hospital delay*, min 90 (50-210) 73 (41-180) 90 (60-210) 0.05 
In-hospital delay, min 166 (90-353) 209 (92-510) 160 (86-322) NS 
Global delay †, min 307 (180-900) 333 (180-1112) 300 (193-840) 0.86 
 
 
*Time from symptom onset to presentation 
 
† Time from symptom onset to diagnosis 
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Table 2 Mechanism of AHF in AAS 
 
 
 
 
 
 
 
 
 
Table 3:  Univariate and multivariate analysis for late in-hospital diagnosis (cutoff > 75
th
 
percentile, 406 min). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Main mechanism Contributing mechanism 
 OVERALL 
N=113 
TYPE A 
N=84 
TYPE B 
N=29 
OVERALL 
N=113 
TYPE A 
N=84 
TYPE B 
N=29 
Cardiac 
Tamponade 
30/113 
(26%) 
30/84 
(36%) 
0/29 
(0%) 
0/113  
(0%) 
0/84 
(0%) 
0/29 
(0%) 
Aortic 
Regurgitation 
29/113 
(25%) 
29/84 
(35%) 
0/29 
(0%) 
9/113  
(8%) 
9/84 
(11%) 
0/29 
(0%) 
Myocardial 
Ischemia 
19/113 
(17%) 
12/84 
(14%) 
7/29 
(24%) 
29/113  
(26%) 
29/84 
(35%) 
0/29 
(0%) 
Hypertensive 
Crisis 
11/113 
(10%) 
1/84 
(1%) 
10/29 
(34%) 
10/113 
(9%) 
4/84 
(5%) 
6/29 
(20%) 
Unknown 24/113 
(21%) 
12/84 
(14%) 
12/29 
(41%) 
   
Variable Univariate analysis Multivariate analysis 
 OR (95% CI) P OR (95% CI) P 
Pleural effusion 2,1 (1,28-3,44) 0,003 2,17 (1,31-3,6) 0,003 
Pericardial effusion 1,67 (1,04-2,68) 0,033   
Acute heart failure 1,43 (0,88-2,32) 0,152   
Male gender 0,75 (0,47-1,21) 0,236   
Pulse deficit 0,50 (0,27-0,92) 0,027 0,56 (0,30-1,05) 0,003 
Back pain 0,48 (0,31-0,77) 0,002 0,51 (0,32-0,81) 0,005 
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Table 4  In-hospital mortality rates in patients with/without AHF 
 
Variable AHF No AHF P value 
Overall AAS 39/113 (34.5%) 48/285 (16,8%) < 0,001 
Type A-AAS 34/84 (40,1%) 34/174 (19,5%) < 0,001 
Type B-AAS 5/29 (17%) 14/111 (12%) 0,731 
 
 
 
Table 5 Univariate and multivariate analysis for in-hospital mortality of AAS patients  
 
 
 
Table 6 Univariate and multivariate analysis for in-hospital mortality of Type A-AAS 
patients  
 
 
 
Variable Univariate analysis Multivariate analysis 
 OR (95% CI) P OR (95% CI) P 
Stanford type A 2,28 (1,30-3,98) 0,004 3,22 (1,65-6,22) 0,001 
Acute heart failure 2,60 (1,58-4,27) <0,001 1,97 (1,14-3,36) 0,014 
Pleural effusion 2,27 (1,36-3,78) 0,002 1,80 (1,03-3,20) 0,043 
ACS-like ECG 2,14 (1,29-3,56) 0,003      1,81 (1,03-3,11) 0,037 
Pericardial effusion 1,82 (1,11-2,98) 0,018   
Troponin positivity 1,63 (0,86-3,09) 0,131   
Pulse deficit 1,5 (0,87-2,56) 0,142 1,70 (0,91-3,01) 0,08 
Age (for each 1 year 
increase) 
1,04 (1,02-1,06) <0,001 1,03 (1,02-1,05) 0,007 
Surgery/EVAR 0,44 (0,22-0,68) 0.001 0,41 (0,21-0,77) 0,006 
Male gender 0,63 (0,39-1,03) 0,067   
Variable Univariate analysis Multivariate analysis 
 OR (95% CI) P OR (95% CI) P 
Acute heart failure 2,80 (1,58-4,97) <0,001 2,40 (1,30-4,51) 0,006 
Pleural effusion 2,98 (1,59-5,57) 0,001 1,98 (1,01-3,97) 0,050 
ACS-like ECG 2,21 (1,21-3,82) 0,011      1,90 (0,99-3,06) 0,056 
Pericardial effusion 1,53 (0,87-2,60) 0,13   
Periaortic effusion 1,92 (0,88-4,22) 0,100   
Age (for each 1 year 
increase) 
1,04 (1,02-1,07) <0,001 1,02 (1,00-1,05) 0,008 
Surgery 0,16 (0,07-0,32) <0,001 0,21 (0,09-0,49) <0.001 
Male gender 0,61 (0,34-1,08) 0,091   
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Table 7 Univariate and multivariate analysis for in-hospital mortality in Type A surgically 
treated patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variable Univariate analysis Multivariate analysis 
 OR (95% CI) P OR (95% CI) P 
Acute heart failure 2,95 (1,51-5,8) 0,002 2,91 (1,4-6,06) 0,004 
Periaortic effusion 2,83 (1,23-6,55) 0,014 2,71 (1,08-6,77) 0,033 
ACS-like ECG 2,19 (1,11-4,34) 0,024 2,49 (1,17-5,29) 0,018 
Pleural effusion 2,15 (1,01-4,56) 0,049   
Abdominal pain 1,7 (0,81-3,57) 0,164   
Age (for each 1 year 
increase) 
1,04 (1,01-1,07) 0,012 1,04 (1,01-1,07) 0,018 
Transfer to “hub” center 0,45 (0,17-1,23) 0,120   
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FIGURE 1 Time to presentation (median values, hours) and time to diagnosis (median values, 
hours) in the overall study population according to the presence of AHF. 
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FIGURE 2 Time to presentation (median values, hours), time to diagnosis (median values, hours), 
and time to surgery (median values, hours)  in Stanford type A AAS according to the presence of 
AHF. 
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CONCLUSIONS 
Troponin positivity is a frequent finding in AAS patients, particularly when a high sensitivity 
assay is employed. The mechanism of troponin release is plausibly multifactorial, including 
coronary dissection, interference between flap and coronary ostia, acute LV pressure 
overload, acute LV volume overload, and shock in patients with or without pre-existing 
coronary disease.  Abnormal troponin values are strongly associated with ACS-like ECG 
findings and with in-hospital diagnostic delay and misdiagnosis, although apparently they do 
not directly influence in-hospital mortality.  
The second main result of our analysis is that AHF  occurs in more than one fourth of patients 
with AAS of both type A and type B, is associated with increased surgical delay and in-
hospital mortality.  AHF was due to a variety of pathophysiological mechanisms including 
cardiac tamponade, aortic regurgitation, myocardial ischemia, hypertensive crisis. 
The awareness of frequency and potential mechanisms of troponin positivity and AHF in 
AAS is essential to guide physicians in this complex and challenging disease.  
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